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A B S T R A C T
Background
Lipid-lowering therapy is recommended for secondary prevention in people with coronary artery disease. It may also reduce cardiovas-
cular events and/or local disease progression in people with lower limb peripheral arterial disease (PAD).
Objectives
To assess the effects of lipid-lowering therapy on all-cause mortality, cardiovascular events and local disease progression in patients with
PAD of the lower limb.
Search methods
The authors searched The Cochrane Peripheral Vascular Diseases Group’s Specialised Register (last searched February 2007) and the
Cochrane Central Register of Controlled Trials (CENTRAL) (last searched Issue 2, 2007) for publications describing randomised
controlled trials of lipid-lowering therapy in peripheral arterial disease of the lower limb.
Selection criteria
Randomised controlled trials of lipid-lowering therapy in patients with PAD of the lower limb.
Data collection and analysis
Three authors independently assessed trial quality and extracted data.
Main results
Eighteen trials were included, involving a total of 10,049 participants. Trials differed considerably in their inclusion criteria, outcomes
measured, and type of lipid-lowering therapy used. Only one trial (PQRST) reported a detrimental effect of active treatment on blood
lipid/lipoprotein levels.
The pooled results from all eligible trials indicated that lipid-lowering therapy had no statistically significant effect on overall mortality
(Odds Ratio (OR) 0.86; 95% Confidence Interval (CI) 0.49 to 1.50) or on total cardiovascular events (OR 0.8; 95% CI 0.59 to
1.09). However, subgroup analysis which excluded PQRST showed that lipid-lowering therapy significantly reduced the risk of total
cardiovascular events (OR 0.74; CI 0.55 to 0.98). This was primarily due to a positive effect on total coronary events (OR 0.76; 95%
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CI 0.67 to 0.87). Greatest evidence of effectiveness came from the use of simvastatin in people with a blood cholesterol ≥ 3.5 mmol/
litre (HPS).
Pooling of the results from several small trials on a range of different lipid-lowering agents indicated an improvement in total walking
distance (Mean Difference (MD) 152 m; 95% CI 32.11 to 271.88) and pain-free walking distance (WMD 89.76 m; 95% CI 30.05
to 149.47) but no significant impact on ankle brachial index (WMD 0.04; 95% CI -0.01 to 0.09).
Authors’ conclusions
Lipid-lowering therapy is effective in reducing cardiovascular mortality and morbidity in people with PAD. It may also improve local
symptoms. Until further evidence on the relative effectiveness of different lipid-lowering agents is available, use of a statin in people
with PAD and a blood cholesterol level ≥ 3.5 mmol/litre is most indicated.
P L A I N L A N G U A G E S U M M A R Y
Lipid-lowering for peripheral arterial disease of the lower limb
Atheroma (fatty deposits) in the walls of the arteries to the legs can lead to peripheral arterial disease with insufficient blood flow to
the muscles and other tissues. People with peripheral arterial disease often do not have symptoms. The most common symptom is
intermittent claudication, which is characterised by leg pain and weakness brought on by walking, with disappearance of the symptoms
following a brief rest. Lipid-lowering therapies may reduce cardiovascular events and worsening of local disease for people with lower
limb peripheral arterial disease. They are recommended to people with coronary artery disease, for prevention of myocardial infarction
and stroke.
Eighteen randomised controlled trials were included in the review, involving a total of 10,049 participants (78% were men) from seven
different countries. The trials compared lipid-lowering therapy with placebo or usual treatment for at least 90 days. They differed
considerably in the inclusion criteria, outcomes measured, and type of lipid-lowering therapy used. Lipid-lowering therapies improved
walking distance. The effect of lipid-lowering therapy on death from any cause in people with peripheral artery disease was inconclusive.
Using drugs to lower blood lipids had a beneficial effect on the incidence of total cardiovascular events, due primarily to an overall
reduction in coronary events (OR 0.8; 95% Confidence Interval 0.7 to 0.9). The only type of drug for which consistent, clear evidence
of a beneficial effect on total cardiovascular events, total coronary events and stroke was available, was the statins. The greatest evidence
was with simvastatin in people with a blood cholesterol level of at least 3.5 mmol/litre. The evidence on side effects was inconclusive
in these trials.
B A C K G R O U N D
Peripheral arterial disease (PAD) in the legs is caused by atheroma
(fatty deposits) in the walls of the arteries leading to insufficient
blood flow to the muscles and other tissues. Patients with PAD
may have symptoms but are often asymptomatic. The commonest
symptom, intermittent claudication, is characterised by leg pain
and weakness brought on by walking, with disappearance of the
symptoms following a brief rest. Approximately 1.5% of people
over 50 years of age have a diagnosis of symptomatic peripheral ar-
terial disease (predominantly intermittent claudication). A further
3% have undiagnosed intermittent claudication and even more
(approximately 11%) have asymptomatic peripheral arterial dis-
ease (Fowkes 1991).
Patients diagnosed as having lower limb PAD, including those
who are asymptomatic, have an increased risk of mortality, my-
ocardial infarction and stroke (Dormandy 1999; Fowkes 1988;
Heald 2006). Relative risks are two to three times that of age and
sex matched groups without PAD. Thus PAD provides a poten-
tial opportunity for secondary prevention of cardiovascular events.
Furthermore, patients with claudication can have a significantly
reduced quality of life due to their restricted mobility (Dumville
2004). Careful consideration therefore needs to be given to evi-
dence on drug and lifestyle management of claudication itself so
that patients can achieve optimum mobility and quality of life
within the limitations of their condition.
This review addresses the question of whether or not lipid-lower-
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ing therapy, which has been shown to be of benefit for secondary
prevention in coronary artery disease patients (SSS Study Group
1994; Sacks 1996; LIPID Study Group), is effective in reducing
the incidence of subsequent cardiovascular events in people with
PAD. The impact of lipid-lowering therapy on local disease pro-
gression and symptoms of PAD (assessed by maximum and pain-
free walking distance) is also considered.
O B J E C T I V E S
Todetermine the effect of lipid-lowering therapy on all-causemor-
tality, cardiovascular events and local disease progression in pa-
tients with lower limb PAD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) of lipid-lowering therapy
versus placebo, or other lipid-lowering therapy or usual care.
Types of participants
Patients with lower limb PAD, including those with intermittent
claudication (diagnosed either by questionnaire or clinically), crit-
ical limb ischaemia or asymptomatic disease (identified by vali-
dated techniques such as angiography or ankle brachial index).
Trials in which all subjects were selected solely on the basis of pre-
vious peripheral vascular interventions were excluded.
Types of interventions
Any lipid-lowering regime used with the aim of reducing blood
lipids. The intervention could be dietary, a hypolipidaemic drug of
themajor classes currently listed in the British National Formulary
(BNF) (fibrates,HMG-CoA reductase inhibitors/statins, nicotinic
acid group, anion exchange resins, Ezetimibe, omega-3 fatty acid
compounds) or any other agent specifically used to lower lipid
levels.
Types of outcome measures
All-cause mortality, fatal and non-fatal cardiovascular events,
revascularization (coronary and non coronary), and direct and in-
direct tests of local disease progression (maximum and pain-free
walking distance, ankle brachial index, angiographic measures)
and side effects of treatment.
Search methods for identification of studies
Electronic searches
The Cochrane Peripheral Vascular Diseases Group searched
their Specialised Register (last searched February 2007) and the
Cochrane Central Register of Controlled Trials (CENTRAL) in
The Cochrane Library (last searched 2007, Issue 2) for publications
describing randomised controlled trials of lipid-lowering therapy
in peripheral arterial disease of the lower limb. For details of the
search strategy used to search CENTRAL see Appendix 1.
The PVD Group’s Specialised Register contains citations of tri-
als identified through back searching and continued prospective
searching of MEDLINE (from 1960 to date), EMBASE (from
1980 to date), CINAHL (1982 to date) and from handsearching
journals and conference proceedings.
The full list of journals that have been handsearched, as well
as the search strategies used to search databases are described
in the editorial information about the Cochrane PVD Group
in The Cochrane Library http://www.mrw.interscience.wiley.com/
cochrane/clabout/articles/PVD/frame.html.
Searching other resources
Additional trials were sought through cross-referencing articles of
lipid lowering, direct contact with principal investigators of trials
in Europe, and (for the original review only) direct contact with
pharmaceutical companies listed as manufacturing lipid-lowering
drugs in theBritishNational Formulary. Therewere no restrictions
for language of publication.
Data collection and analysis
Selection of trials
Three authors (PPA, HM and RJ) selected potential trials and
assessed their eligibility for inclusion in the update of this review.
Any disagreements were resolved by a fourth author (JP).
Assessment of trial quality
The quality of included trials was assessed for both allocation con-
cealment and for internal and external validity using a standard
scoring sheet developed by the PVD Group. For each included
trial, information was collected on the method of randomisation,
blinding andwhether an intention-to-treat analysis had beendone.
For this update, three authors (PPA, HM and RJ) assessed trial
quality and the results were cross-checked by JP.
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Data extraction
For this update PPA , HM and RJ independently extracted data
and discrepancies were resolved in discussion with a fourth author
(JP). We sought additional information to that appearing in pub-
lished reports from the principal investigators when required.
We extracted data for the following outcomes and considered them
for pooled analysis.
1. All-cause mortality.
2. Cardiovascular events - total, fatal and non-fatal.
3. Coronary events - total, fatal and non-fatal.
4. Stroke - total, fatal and non-fatal.
5. Revascularizations (coronary and non-coronary).
6. Walking distance - pain free and total.
7. Ankle Brachial Index (ABI).
8. Disease progression assessed by angiogram.
9. Side effects.
Data analysis
Homogeneity between trial results was tested subjectively by clin-
ical judgment of differences in patient populations, interventions
and outcome assessments, and objectively using appropriate sta-
tistical tests. Where appropriate, trial results were pooled using
relevant statistical techniques. We performed subgroup analyses
for all trials excluding those reported as having a detrimental effect
on lipid/lipoprotein parameters. We performed further subgroup
analyses for trials with only the highest quality assessment and for
trials confined to a single class of lipid-lowering therapy. Although
publication bias could not be excluded, there proved to be an in-
sufficient number of trials for each outcome to assess this formally.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
In the original version of this review there were seven included
studies and two excluded studies. We identified 62 new trials, of
which 49 were excluded. In addition, we excluded two trials in-
cluded in the original review (CLAS;Davis 1975). The former trial
was excluded because participants included were not only those
suffering from lower limb atherosclerosis but also unaffected sub-
jects. The trial by Davis et al was excluded because only subjective
symptom changes were reported and newer trials provide an in-
creased quantity of evidence on objective measures. For additional
information on excluded studies, see Characteristics of excluded
studies table.
No studies were excluded from the review purely due to poor
methods, but the results of methodological quality scoring were
used to exclude trials from subgroups in the meta-analysis. Four
trials are awaiting further assessment (Borreani 1993; Degni
1973; Di Stefano 1984; Mayer 2001). Despite many attempts,
two references have proved to be unobtainable (Degni 1973; Di
Stefano 1984); the remaining two require detailed translation
(Borreani 1993; Mayer 2001) (Characteristics of studies awaiting
classification).
A total of 13 new studies involving a total of 10,049 subjects were
included in this update, including one previously ongoing study
(LEADER). The number of subjects participating in each study
ranged from 19 to 6748.
The earliest study was published in 1973 (Nye 1973) and the
most recent with relevant results in 2007 (HPS). Eight studies
were from Italy, three from the UK, and three from Cuba. The
remaining studieswere fromUSA,TheNetherlands,NewZealand
and Sweden. Except for the LEADER trial, which was confined
to men, there was no sex restriction. Men constituted 78% of the
total number of study participants (n=7832). Duration of follow
up ranged from 20 days to five years.
Trials differed in the criteria they used to define peripheral arterial
disease of the lower limb (PAD) in trial participants. The majority
used a combination of clinical symptoms (predominantly inter-
mittent claudication) with or without confirmation using objec-
tive tests such as Doppler ultrasound, treadmill tests and/or an-
giography.
In the Nye study (Nye 1973) and HPS (HPS), patients who
had undergone surgery for PAD were also included. HPS used
a broad definition for PAD, including subjects with intermittent
claudication, any peripheral revascularization procedure, or aortic
aneurysm. Patients with diabetes and treated hypertension were
also included inHPS butwere excluded in some other studies. The
LEADER trial used the Edinburgh Claudication questionnaire to
identify PAD.
Five studies (HPS; LEADER; Mondillo 2003; PQRST; St
Thomas’ Trial) used minimum blood lipid and/or lipoprotein lev-
els as inclusion criteria; one trial used a maximum LDL cholesterol
level of ≤ 4.14 mmol/l (Mohler 2003).
All studies were on drug interventions except one study (Gans
1990) which used fish oil. The majority investigated a single
drug against placebo and/or usual treatment. Three of these were
on statins; two on simvastatin (HPS; Mondillo 2003), and one
on atorvastatin (Mohler 2003); one on probucol, (probucol and
cholestyramine versus cholestyramine alone) (PQRST); one on
beta pyridil (Nye 1973); one on bezafibrate (LEADER); two
on policosanol (fatty alcohol) (Castano 1999; Castano 2001);
and seven on sulodexide (a glycosaminoglycan with lipid-lower-
ing properties) (Bonalumi 1986; Caramelli 1988; Coccheri 2002;
Corsi 1985; Cospite 1985; Liguori 1993; Palmieri 1984). In ad-
dition, Castano 2003 compared policosanol with lovastatin; and
in the St Thomas’ Trial, participants in the active treatment group
were allocated cholestyramine and/or nicotinic acid or clofibrate
or nicotinic acid, depending on their type of hyperlipidaemia (ver-
4Lipid-lowering for peripheral arterial disease of the lower limb (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
sus usual care).
Three studies did not report on the effects of treatment on
blood lipid profiles over the course of the trial (Caramelli 1988;
Castano 1999; Coccheri 2002). The other studies (Bonalumi
1986; Castano 2001; Castano 2003; Corsi 1985; Cospite 1985;
HPS; LEADER; Mohler 2003; Mondillo 2003; Nye 1973; St
Thomas’ Trial) reported a decrease in total and/or low density
lipoprotein cholesterol levels and an increase in protective high
density lipoprotein (HDL) cholesterol levels. The only exceptions
were (i) Gans 1990 and Palmieri 1984 in which total and/or
LDL cholesterol levels remained unchanged (in Gans 1990, HDL
cholesterol increased, and in Palmieri 1984 triglyceride levels de-
creased) and (ii) PQRST, inwhich decreased total andLDLcholes-
terol levels were associated with a decrease also inHDL cholesterol
levels.
For additional information on included studies, seeCharacteristics
of included studies table.
Risk of bias in included studies
Methodological quality was assessed using the following criteria
and in accordance with the guidelines provided by the Cochrane
Peripheral Vascular Diseases Group based on the Cochrane
Handbook for Systematic Reviews of Interventions (Cochrane
Handbook).
• Method of allocation and concealment of allocation
• Treatment and control group comparable at entry
• Use of intention-to-treat analysis
• Adequate blindness
For each criterion of internal validity, we graded studies as low
risk of bias (A) if they fully met the criterion, moderate risk (B)
if they partly met the criterion and high risk (C) if they failed to
meet the criterion. Overall quality of each study was rated as A if
the study scored A in all criteria, B if one or more of the criteria
scored B and C if one or more of the criteria scored C. A detailed
breakdown of the scoring is shown in the table of methodological
quality assessment of included studies (Table 1).
Information on provider blindness to the assignment status and
observer variation in outcome measurements was not available for
the included studies and therefore these quality criteria were not
assessed in the review. Loss to follow up was also not used for
quality assessment, as it was difficult to grade, but is described in
the table of methodological quality assessment. External validity
was also assessed by clear definition of inclusion and exclusion
criteria as well as outcome reported but this was not used in the
overall grading of studies.
For further information on methodological quality assessment, see
additional table (Table 1).
Effects of interventions
Trials comparing lipid-lowering therapywith placebo and/or usual
treatment for at least 90dayswere included inmeta-analysis. There
were insufficient trials comparing one lipid-lowering therapy with
another to enable pooling.
Many of the data on all-cause mortality, fatal and non-fatal cardio-
vascular events were obtained from information given on reasons
for participant withdrawal from the trial, rather than forming a
primary and prespecified outcome measure. In such cases, studies
were generally under-powered to investigate these outcomes. In
many trials fatal and non-fatal cardiovascular events were reported
separately and it was not clear whether only the first event was
recorded for a given individual. Therefore, where cardiovascular
event rates were created by adding together fatal and non-fatal
cardiovascular events for the purposes of pooling results from dif-
ferent trials, it is possible that subjects with both a fatal and a non-
fatal event have been counted twice.
The included studies were not necessarily statistically diverse on
tests of heterogeneity but were clinically varied. Therefore, we
pooled results using a random-effects model for meta-analysis. We
performed subgroup analyses excluding (i) those studies graded
as having a high or moderate risk of bias and (ii) the PQRST
trial, which had an adverse effect on lipoprotein profile (HDL
cholesterol was reduced by 24% in those on probucol). We also
performed subgroup analyses of studies using the same class of
lipid-lowering therapy for every outcome wherever possible. Only
three classes of drugs - statins, policosanol and sulodexide (the
latter for walking distance only), were tested in more than one trial
and were therefore subject to this sub-group analysis
1. All-cause mortality (Analysis 01/01)
Information on all-causemortality was reported in only six studies,
of which three (Castano 1999; Castano 2001; Nye 1973) were not
designed to look at this outcome.
The pooled result from all six studies indicated that there was no
statistically significant effect of lipid-lowering therapy on all-cause
mortality (odds ratio (OR) 0.86; 95% confidence interval (CI)
0.49 to 1.50, P = 0.60). Exclusion of PQRST from the analysis did
not change this finding (OR 0.92; CI 0.54 to 1.57, P = 0.75). The
result was similar when additional studies with high or moderate
risk of bias were excluded (OR 0.84; CI 0.36 to 1.96, P = 0.68).
In a pooled subgroup analysis of the two small Castano studies
of policosanol versus placebo a lower risk of all-cause mortality
among those treated with policosanol was not statistically signifi-
cant (OR 0.19; 95% CI 0.02 to 1.71, P = 0.14).
2. Cardiovascular events
For further information on events contributing to vascular out-
comes, see additional table (Table 2).
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(a) Total cardiovascular events (fatal and non-fatal) Analysis
01/02
A total of eight studies were included in this analysis, including the
large PAD subgroup of theHPS study.Onpooling the results of all
studies, treatment was associated with a non-significant reduction
in the risk of total cardiovascular events (OR 0.80; 95% CI 0.59
to 1.08, P = 0.14). The HPS and LEADER trials contributed 53%
and 30% of the weight to this result respectively. The pooled result
was similar when all studies with moderate or high risk of bias were
excluded (OR 0.76; 95% CI 0.54 to 1.07, P = 0.12). However,
when the PQRST trial alone was excluded, the reduction in risk
was statistically significant (OR 0.74; 95% CI 0.55 to 0.98, P =
0.04).
Two studies investigated the effects of statins on total cardiovas-
cular events (simvastatin 40 mg daily in HPS and atorvastatin ei-
ther 10 mg or 80 mg daily in Mohler 2003). The total number
of participants was 7002 (95% in the HPS). A pooled subgroup
analysis of these two studies demonstrated a statistically significant
lower risk of a cardiovascular event among those taking HMGCO
A lipid-lowering therapy compared with placebo (OR 0.74; 95%
CI 0.67 to 0.82, P < 0.00001). Since one third of the patients
in HPS had undergone coronary or peripheral vascular surgery, it
is possible that the effect of simvastatin on this group may differ
from those without such co-morbidity or advanced disease.
Pooled subgroup analysis of the two Castano studies (Castano
1999; Castano 2001) indicated a statistically significant lower risk
of a cardiovascular event among those taking policosanol com-
pared with placebo (OR 0.06; 95% CI 0.01 to 0.46, P = 0.007).
(b) Fatal cardiovascular events (Analysis 01/03)
Of the eight studies which reported on total cardiovascular events,
one did not distinguish between fatal and non-fatal events (HPS)
and one other gave only non-fatal cardiovascular events as a sep-
arate category (Mohler 2003). Therefore, only six studies were
available for pooled analysis on this outcome, the result of which
was heavily influenced by the LEADER trial (giving over 93% of
the weight to the overall pooled result). There was no statistically
significant difference in the risk of a fatal cardiovascular event be-
tween the treatment and placebo groups when all six studies were
pooled (OR 0.96; 95% CI 0.70 to 1.33, P = 0.81), nor when
PQRST was excluded (OR 0.97; 95% CI 0.70 to 1.35, P = 0.87),
nor when additional studies with moderate or high risk of bias
were excluded (OR 1.02; 95% CI 0.73 to 1.43, P = 0.89).
Pooled results from the two Castano studies showed no statisti-
cally significant difference in fatal cardiovascular events between
policosanol and placebo (OR 0.33; 95% CI 0.03 to 23.30, P =
0.35).
(c) Non-fatal cardiovascular events (Analysis 01/04)
Of the seven studies which reported this outcome, the LEADER
and PQRST trials contributed approximately 42% and 31% of
weight to the overall pooled result respectively. There was no sta-
tistically significant difference in non-fatal cardiovascular events
between treatment and placebo groups when all seven studies were
pooled (OR 0.80; CI 0.48 to 1.34, P = 0.40), nor when PQRST
was excluded (OR 0.64; 95% CI 0.36 to 1.13, P = 0.12), nor
when additional studies with moderate to high risk of bias were
excluded (OR 0.25; 95% CI 0.03 to 0.56, P = 0.17).
In subgroup analysis of the two Castano trials, there was a sta-
tistically significant lower risk of a non-fatal cardiovascular event
among those receiving policosanol compared with placebo (OR
0.07; 95% CI 0.01 to 0.56, P=0.01).
3. Coronary events
(a)Total coronary events (Analysis 01/05)
A total of eight studies were included in this analysis, including
the large HPS and LEADER trials. On pooling the results of all
studies, treatment was associated with a statistically significant
reduction in the risk of total coronary events (OR 0.80; 95% CI
0.66 to 0.96, P = 0.01). The HPS and LEADER trials contributed
76% and 18% of the weight to this result respectively. The pooled
result was similar when the PQRST trial alone was excluded (OR
0.76; 95% CI 0.67 to 0.87, P < 0.0001) and when additional
studies withmoderate or high risk of bias were excluded (OR 0.76;
95% CI 0.67 to 0.87, P < 0.0001).
A pooled subgroup analysis of the two studies investigating the
effects of statins on total coronary events (HPS; Mohler 2003),
demonstrated a statistically significant lower risk of a cardiovas-
cular event among those taking HMG CO A lipid-lowering ther-
apy compared with placebo (OR 0.77; 95% CI 0.66 to 0.89, P =
0.0003).
Pooled subgroup analysis of the two Castano studies suggested
a lower risk of a coronary event among those taking policosanol
comparedwith placebo (OR0.20; 95%CI 0.02 to 1.85, P = 0.16).
However, the effect was not statistically significant.
(b) Fatal coronary event (Analysis 01/06)
As with the total cardiovascular event outcome, the large HPS
study did not differentiate between fatal and non-fatal coronary
events and was therefore not included in the analyses of coronary
events by ’fatal’ or ’non-fatal’. Five studies did report on fatal coro-
nary events separately, the pooled results for which were heavily
influenced by the LEADER trial. There was no statistically sig-
nificant difference in fatal coronary events between the treatment
and placebo groups with all eligible trials included (OR 0.94; 95%
CI 0.66 to 1.33, P = 0.71), nor when PQRST was excluded (OR
0.95; 95% CI 0.67 to 1.34, P = 0.76). Exclusion of studies with
moderate to high risk of bias left only the LEADER trial.
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(c) Non-fatal coronary events (Analysis 01/07)
Six studies reported this outcome separately. The pooled result
showed no statistically significant difference in non-fatal coronary
events between the treatment and placebo groups (OR 0.73; 95%
CI 0.37 to 1.45, P = 0.38). The LEADER trial contributed 53%
of weight to this result. However, when PQRST was excluded,
the pooled result showed a statistically significant lower risk of a
non-fatal coronary event among those treated with lipid-lowering
therapy compared with those taking placebo (OR 0. 54; 95%
CI 0.34 to 0.86, P = 0.009). This result was maintained when
additional studies withmoderate to high risk of bias were excluded
(OR 0.53; 95% CI 0.33 to 0.85, P = 0.009).
The pooled result from the two Castano studies (Castano 1999;
Castano 2001) suggested a reduction in non-fatal coronary events
in those taking policosanol (OR 0.20; 95% CI 0.02 to 1.85, P =
0.16) but the effect was not statistically significant.
4. Total stroke (Analysis 01/08)
A total of six studies were included in this analysis, including
the large HPS and LEADER trials. On pooling the results of all
studies, there was no statistically significant effect of treatment on
the risk of combined fatal and non-fatal stroke (OR 0.88; 95% CI
0.58 to 1.33, P = 0.54). The HPS and LEADER trials contributed
64% and 33% of the weight to this result respectively. The pooled
result was similar when all studies with moderate or high risk of
bias were excluded (OR 0.86; 95% CI 0.52 to 1.41, P = 0.54).
A pooled subgroup analysis of the two studies that investigated
the effects of statins on total stroke events (HPS; Mohler 2003),
demonstrated a lower risk of statistically significant stroke among
those taking lipid-lowering therapy compared with placebo (OR
0.72; 95% CI 0.59, 0.88, P = 0.001).
Pooled subgroup analysis of the two Castano studies (Castano
1999; Castano 2001) indicated no statistically significant differ-
ence in risk of stroke between those taking policosanol and placebo
(OR 0.19; 95% CI 0.02, 1.71, P = 0.14)
(a) Fatal stroke (Analysis 01/09)
The large HPS study did not differentiate between fatal and non-
fatal stroke and could not be included in the analyses of these
outcomes separately. Five studies (but not the PQRST trial) did
report on fatal stroke, the pooled results for which were once more
heavily influenced by the LEADER trial. There was no statistically
significant difference in risk of fatal strokes between the treatment
and placebo groups when all trial were combined (OR 1.14; 95%
CI 0.54 to 2.43, P = 0.73), nor when studies with moderate to
high risk of bias were excluded (OR 1.22; 95% CI 0.55 to 2.71,
P = 0.63).
Pooled result from the two Castano studies (Castano 1999;
Castano 2001) showed no statistically significant difference in fa-
tal stroke events between policosanol and placebo (OR 0.33; 95%
CI 0.03 to 3.30, P = 0.35).
(b) Non-fatal stroke (Analysis 01/10)
The same five studies reported this outcome, with the LEADER
trial contributing over 90% of weight to the pooled result. The
overall pooled result showed no statistically significant difference
in risk of non-fatal stroke between treatment and placebo (OR
1.16; 95% CI 0.76 to 1.77, P = 0.48). This remained the case
when studies with moderate to high risk of bias were excluded
from the analysis (OR 1.14; 95% CI 0.74 to 1.74, P = 0.55). In
further subgroup analysis, the pooled result from the two Castano
trials showed no statistically significant difference in risk of non-
fatal stroke events between policosanol and placebo (OR 0.33;
95% CI 0.03 to 3.30, P = 0.35).
5. Revascularizations (Analysis 01/11)
Two studies (HPS; Mohler 2003) assessed the impact of lipid-
lowering therapy (HMG CO A group) on risk of coronary and
non-coronary procedures. The pooled result showed a statistically
significant decrease in revascularization rate among those taking
lipid-lowering therapy compared with placebo (OR 0.73; 95%CI
0.64 to 0.83, P < 0.00001). The result was heavily influenced by
HPS which contributed over 99% of weight to the result.
6. Walking distance
Eleven studies reported on walking distance (Bonalumi 1986;
Caramelli 1988; Castano 1999; Castano 2001; Castano 2003;
Corsi 1985; Cospite 1985; Gans 1990; Liguori 1993; Mondillo
2003; Palmieri 1984) of which only seven reported numerical data
and were suitable for pooling by meta-analysis. Of the remainder,
Bonalumi et al (Bonalumi 1986) reported that treatment with su-
lodexide for 90 days doubled walking distance compared with no
change in the placebo group but accurate numerical data could not
be extracted from the graphs provided. Liguori 1993 reported that
treatment with sulodexide for the same duration resulted in a sta-
tistically significant improvement over placebo (5.7 m in placebo
group versus 28.8 m, 50 m and 38.9 m in sulodexide groups de-
pending on dosage). Caramelli 1988 reported a statistically signif-
icant difference in pain-free walking distance between the treat-
ment group (mean 233.44 m, SD 115.02) and the placebo group
(mean 156.60 m, SD 109.57, P < 0.05), but since the duration
of treatment was limited to 20 days, this trial did not reach our
criterion of a minimum of 90 days duration for inclusion in the
meta-analysis.
In the small (n = 28) trial by Castano (Castano 2003), both pain-
free and total walking distance increased more in the policosanol
group (33.7% and 24.3% increases from baseline) compared with
the lovastatin group (12.3% and 4.9% increases from baseline, P
< 0.01 for comparison with policosanol group).
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(a) Pain-free walking distance (Analysis 01/12)
Seven studies were included in the analysis of this outcome
(Castano 1999; Castano 2001; Corsi 1985; Cospite 1985; Gans
1990; Mondillo 2003; Palmieri 1984). The pooled result showed
a statistically significant improvement in walking distance with
lipid-lowering therapy compared with placebo (mean difference
(MD) 89.76 m; 95% CI 30.05 to 149.47, P = 0.003).
In subgroup analysis of the two Castano trials (Castano 1999;
Castano 2001), there was a statistically significant improvement in
pain-freewalkingdistance amongpatients treatedwith policosanol
compared with those taking placebo (MD 131.80 m; 95% CI
14.97 to 248.64, P = 0.03). However, an improvement in pain-
free walking distance suggested by pooling the results of three trials
using sulodexide was not statistically significant (MD 94.15 m;
95% CI -5.33 to 193.62, P = 0.06).
(b) Total walking distance (Analysis 01/13)
Four studies reported this outcome and were pooled (Castano
1999; Castano 2001; Gans 1990; Mondillo 2003). There was a
statistically significant improvement in total walking distance with
lipid-lowering therapy compared with placebo (MD 152.00 m;
95% CI 32.11 to 271.88, P = 0.01).
Pooled subgroup analysis of the two Castano studies (Castano
1999; Castano 2001) also indicated a statistically significant im-
provement in total walking distance among those taking poli-
cosanol compared with placebo (MD 274.48 m; 95% CI 9.21 to
539.74, P = 0.04).
7. Ankle brachial index (ABI) (Analysis 01/14)
A total of six studies were included in this analysis and were pooled
(Castano 1999; Castano 2001; Corsi 1985; Gans 1990; Mohler
2003; Mondillo 2003). There was no statistically significant dif-
ference in ABI following treatment between the intervention and
placebo groups (MD 0.04; 95% CI -0.01 to 0.09, P = 0.09).
Pooled subgroup analyses indicated no significant effect on ABI
of either policosanol (MD 0.07; 95% CI -0.05 to 0.18, P = 0.28)
(Castano 1999; Castano 2001) or statin (MD 0.05; 95% CI -0.03
to 0.13, P = 0.22) (Mohler 2003; Mondillo 2003).
For the last three outcomes (PFWD, TWD and ABI), the two
Castano studies were the only studies graded as A in quality as-
sessment.
8. Disease progression assessed by angiogram
Two studies (PQRST; St Thomas’ Trial) looked at this outcome.
Meta-analysis was not possible because of different summary mea-
surements reported.
In the St Thomas’ Trial, disease progression, assessed using femoral
arteriography was reduced significantly in the treatment group
(10/144 arterial segments) compared with the placebo group (27/
156 arterial segments P < 0.01).
In the PQRST trial probucol did not show a favourable effect on
femoral artery lumen volume (0.6% increase in volume from base-
line, P = 0.61) compared with placebo (4.2% increase in volume
from baseline, P < 0.001).
9. Side effects
No major side effects were detected in those taking sulodexide
(Bonalumi 1986; Caramelli 1988; Corsi 1985; Liguori 1993), ex-
cept for pain at the injection site and transient and sporadic epi-
gastric heaviness and/or heartburn. No major side effects were ex-
perienced in subjects taking essential fatty acid supplements (Gans
1990). Betapyridyl carbinol produced gastrointestinal symptoms
in seven out of the 23 patients at a dosage of 1800 mg daily (Nye
1973), but only three patients were unable to tolerate 1200 mg
daily. In addition, two male patients developed liver toxicity in
response to treatment. No major side effects were noted in pa-
tients receiving probucol therapy (PQRST). However, a reduction
in the beneficial HDL cholesterol levels may be interpreted as an
adverse reaction in those on probucol. Side effects were not given
in the available reports from the St Thomas’ Trial (Duffield 1982;
Duffield 1983; Lewis 1985).
The Heart Protection Study reported that there was no increase
in the incidence of cancer associated with simvastatin, except for
a slight increase in the incidence of non-melanoma skin cancer
(HPS). The authors noted however that the incidence of this skin
cancer did not increase with prolonged treatment, arguing against
a causal relationship. The Leader trial reported no adverse effect
on cancer incidence associated with bezafibrate, but a statistically
significant higher number of patients on active treatment with-
drew due to raised serum creatinine level compared with placebo
(LEADER).
No information was provided on side effects for the trial using
atorvastatin (Mohler 2003).
Policosanol was reported as well tolerated (Castano 1999; Castano
2001; Castano 2003). There weremild side effects (asthenia, mus-
cular cramps/pain, and granuloma) reported for lovastatin 20 mg
daily (Castano 2003).
D I S C U S S I O N
Thirteen additional studies were included in this firstmajor update
compared with the original version of the review . This was due
to the results of studies still in progress at the time of the original
review becoming available and an improved search facility which
identified earlier studies (for example, Palmieri 1984) as well as
the completion of new relevant trials.
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Differences in included studies compared with
original review
Compared with the original review, this update included two stud-
ies on statins: the Heart Protection Study which used simvastatin
40 mg daily (HPS) and a smaller study by Mohler (Mohler 2003)
using atorvastatin 10 mg or 80 mg daily. Other groups of drugs
which were added included sulodexide and policosanol, although
these drugs are not currently listed as lipid-lowering drugs in the
British National Formulary (BNF).
Compared with studies included in the original review, the largest
study added to this update used a wider definition of periph-
eral arterial disease (HPS). Of 6748 participants with a history of
PAD, around one third had undergone previous peripheral arterial
surgery, which included aortic revascularization procedures and
aneurysm repair, angioplasty or a previous amputation (2%). We
were unable to obtain the results of the HPS excluding those with
aortic disease from the trial investigators. The Nye study (Nye
1973) , which was included in the original version of the review,
also included some patients who had undergone peripheral arte-
rial surgery in its study population. We had pre-specified for this
review that studies of lipid lowering solely in post-procedural pa-
tients with PADwould be excluded, in part because these trials are
concerned with re-stenosis or procedure failure rates rather than
long-term cardiovascular morbidity and mortality. However, we
made the decision to include studies with a mix of symptomatic
and post-procedural subjects due to the likely similar underlying
pathology and consistency in outcomes measured with other in-
cluded trials.
In terms of aortic disease, most of the included studies did not
mention aortic disease or surgery in their inclusion or exclusion
criteria. It was therefore decided to omit the clause ’aortic disease’
from the exclusion criteria used in the original version of the review
(which was originally intended to exclude entire studies on aortic
disease).
In contrast with the original review, the CLAS study (CLAS) was
excluded from this update because participants included not only
those suffering from lower limb atherosclerosis but also unaffected
subjects. Davis 1975 was also excluded because only subjective
symptom changes were reported and newer trials provide an in-
creased quantity of evidence on objective measures.
Studies which did not suggest a favourable effect
on outcomes
Overall, the vastmajority of individual trials suggested a favourable
effect on outcomes although only some of these were statistically
significant. Exceptions to this were the studies byMohler (Mohler
2003), Gans (Gans 1990) and the LEADER and PQRST trials. It
is worth noting that the study by Mohler (Mohler 2003) was not
designed to detect all-cause mortality or cardiovascular events and
relatively few such events were recorded in either the treatment
or placebo groups. Gans 1990 suggested a reduction in walking
distance on active treatment (fish oil), but results were not statis-
tically significant.
The PQRST trial was not designed to detect fatal and non-fatal
cardiovascular events but to assess disease progression measured by
femoral angiography. Results showed that probucol (in addition
to existing cholestyramine treatment) did not impact on femoral
atherosclerosis. Probucol was found to have an adverse effect on
the lipid profile in participants assigned active treatment. Thus,
plasma high density lipoprotein (HDL) cholesterol was decreased
by as much as 24% in the probucol group compared with those
on placebo. The authors concluded that very low levels of HDL
in probucol treated patients possibly counteracted the observed
beneficial effect of treatment on plasma low density lipoprotein
cholesterol level . Probucol is currently not listed as a lipid-lowering
drug in the British National Formulary (BNF).
The LEADER trial was designed to detect the combined incidence
of coronary heart disease and stroke (fatal and non-fatal) as its
primary outcome and separate fatal and non-fatal coronary and
stroke events as secondary outcomes. Bezafibrate did not reduce
the incidence of fatal events but did reduce the incidence of non-
fatal coronary events. In post-hoc subanalysis, bezafibrate also de-
creased total coronary events (RR 0.13; 95% CI 0.03 to 0.56)
among those aged under 65 years. Several factors need to be taken
into account in interpreting the result of the LEADER trial, which
heavily influenced the pooled results on fatal and non-fatal cardio-
vascular events, and all-cause mortality in this review. Firstly, there
was an increased use of statins in the placebo group; more subjects
from the placebo group (109 out of 403 subjects) compared with
those on active treatment (42 out of 369) withdrew because they
were prescribed lipid-lowering therapy (predominantly a statin).
Secondly, the primary outcome measure of combined fatal and
non-fatal cardiovascular events did not reach the level required by
the author’s sample size calculation; it was estimated that 33% of
the placebo group would develop a primary end-point during four
years follow up whereas the actual observed event rate was 20.4%.
Although bezafibrate improved the blood lipid profile of partici-
pants (reducing plasma total cholesterol, low density lipoprotein
cholesterol and triglycerides and increasing high density lipopro-
tein cholesterol), it was also reported that bezafibrate increased
plasma homocysteine concentrations, which may be a risk factor
for vascular diseases in high concentrations.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The effect of lipid-lowering therapy on all-cause mortality in peo-
ple with PAD was inconclusive, probably due to lack of large scale
and long duration trials measuring this outcome. However, lipid-
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lowering therapy had a beneficial effect on the incidence of to-
tal cardiovascular events due primarily to a reduction in coronary
events. Lipid-lowering therapy also improved walking distance.
There was insufficient evidence to compare the effectiveness of
different lipid-lowering regimens. However, the only class of drug
for which consistent and statistically significant evidence of a ben-
eficial effect on total cardiovascular events, total coronary events
and stroke was available, was the statins. This evidence came from
the HPS, in which simvastatin was assigned to subjects with PAD
and a random blood total cholesterol level of at least 3.5 mmol/l.
As such, lipid-lowering therapy with a statin is recommended for
patients with peripheral arterial disease and total cholesterol levels
> 3.5 mmol/l.
Implications for research
Further research is indicated to compare the relative effectiveness
of different lipid-lowering therapies in people with PAD. How-
ever, because of increasing use of statins in clinical practice, the
opportunities to undertake such trials may be limited. Because
of the relatively large number of people with asymptomatic PAD
(detected for instance using measures of ankle brachial index), re-
search into the effectiveness of lipid-lowering therapy in such sub-
jects should be considered.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bonalumi 1986
Methods Study design: double blind, randomised controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not stated.
Exclusions post randomisation: not stated.
Losses to follow up: not stated.
Intention to treat: no.
Participants Country: Italy.
Setting: hospital.
No: 30 (15 per group).
Age: (mean) sulodexide 60.1 ± 8.6; placebo 60.4 ± 9.6.
Sex: sulodexide, males 14, females 1; placebo, males 11, females 4.
Inclusion Criteria: “patients with PVD”.
Exclusion criteria: not stated.
Interventions Treatment: sulodexide 2 vials i.m. per day for 20 days followed by 4 capsules daily for 70 days.
Control: placebo i.m. twice daily followed by 4 placebo capsules daily for 70 days.
Duration: 90 days
Outcomes Walking distance, symptom scores (pain, cramps, tingling, dulled sensations) biochemical and hamato-
logical parameters
Notes Biochemical and haematological parameters measured pre, during and at end of study. Active treatment
associated with reduced tChol and VLDL and increased HDL
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Caramelli 1988
Methods Study design: double blind, randomised, placebo-controlled trial.
Method of randomisation: randomisation list.
Concealment of allocation: not stated.
Exclusions post randomisation: none.
Losses to follow up: none.
Intention to treat: not stated in the article but all patients accounted for in analysis
Participants Country: Italy.
Setting: hospital.
No: 60.
Age: (mean) 60.01 ± 8.27.
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Caramelli 1988 (Continued)
Sex: males 52; females 8.
Inclusion criteria: PAD assessed by Doppler, plethysmography.
Exclusion criteria: none stated.
Interventions Treatment: sulodexide one 300 LRU vial of i.m. twice daily.
Control: placebo i.m. vials twice daily.
Duration: 20 days.
Outcomes Pain-free and total walking distance; subjective parameters (night pain intensity, sense of coldness in lower
limbs) confirmed using Doppler
Notes Biochemical outcomes measured pre and post study but not reported
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Castano 1999
Methods Study design: double blind, randomised, placebo-controlled trial.
Method of randomisation: computer generated using balanced blocks without stratification (randomisa-
tion ratio 1:1).
Concealment of allocation: details of medication sealed in sequentially numbered identical containers
according to progressive inclusion order.
Exclusions post randomisation: none.
Losses to follow up: policosanol 3; placebo 7
Intention to treat: yes.
Participants Country: Cuba.
Setting: hospital outpatients.
No: 62.
Age: (mean) policosanol 59 ± 11; placebo 60 ± 11.
Sex: policosanol, males 27, females 4; placebo, males 23 females 8.
Inclusion criteria: ICD 50 to 300 metres; absolute claudication distance < 500 metres.
Exclusion criteria: > 80 years; MI; vascular surgery; unstable angina or stroke 3 months before the study;
severe hypertension; occlusive thromboangiitis; congenital or acquired haemorrhagic diseases; pregnant
or nursing women
Interventions Treatment: policosanol 10 mg tablets twice daily.
Control: placebo tablets twice daily.
Duration: 6 months.
Outcomes Primary: initial claudication distance; absolute claudication distance; ABPI.
Secondary: pain; parethesia and coldness in lower limbs.
Side effects: adverse effects and tolerability.
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Castano 1999 (Continued)
Notes Some patients had hypercholesterolemia.
Biochemical outcomes not measured.
ABPI recorded as ankle/arm pressure ratio of the worst lower limb.
Authors used terms initial (ICD) and absolute claudication distance (ACD). For comparison we used
pain-free and total walking distance.
Authors contacted for additional information on trial. Response received
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Castano 2001
Methods Study design: double blind, randomised, placebo-controlled trial.
Method of randomisation: computer generated using balanced blocks without stratification (randomisa-
tion ratio 1:1).
Concealment of allocation: details of medication sealed in sequentially numbered identical containers
according to progressive inclusion order.
Exclusions post randomisation: none.
Losses to follow up: policosanol 4; placebo 12.
Intention to treat: yes.
Participants Country: Cuba.
Setting: hospital outpatients.
No: 56.
Age: (mean) policosanol 59 ± 11; placebo 59 ± 11.
Sex: policosanol, males 24, females 3; placebo, males 22, females 7.
Inclusion criteria: ICD 50 to 300 metres.
Exclusion criteria: > 80 years; MI; vascular surgery unstable angina or stroke 3 months before the study;
severe hypertension; occlusive thromboangiitis; congenital or acquired haemorrhagic diseases; pregnant
or nursing women
Interventions Treatment: policosanol 10 mg tablets twice daily.
Control: placebo tablets twice daily.
Duration: 24 months.
Outcomes Primary: initial claudication distance; absolute claudication distance; ABPI.
Secondary: pain; parethesia and coldness in lower limbs.
Side effects: adverse effects and tolerability.
Notes Some patients had hypercholesterolemia.
Biochemical outcomes measured and recorded pre, during, and post study.
ABPI recorded as ankle/arm pressure ratio of the worst lower limb.
Authors used terms initial (ICD) and absolute claudication distance (ACD). For comparison we used
pain-free and total walking distance.
Authors contacted for additional information on trial. Response received.
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Castano 2001 (Continued)
Active treatment associated with reduced tChol and LDL and increased HDL
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Castano 2003
Methods Study design: double blind, randomised, controlled, pilot trial.
Method of randomisation: computer generated using balanced blocks without stratification (randomisa-
tion ratio 1:1).
Concealment of allocation: details of medication sealed in sequentially numbered identical containers
according to progressive inclusion order.
Exclusions post randomisation: none.
Losses to follow up: policosanol 0; lovostatin 1.
Intention to treat: yes.
Participants Country: Cuba.
Setting: hospital outpatients.
No: 28.
Age:(mean) policosanol 60 ± 9; lovostatin 65 ± 9.
Sex: policosanol, males 10, females 4; lovastatin, males 11, females 3.
Inclusion criteria: ICD 50 to 300 metres; ACD < 500 metres.
Exclusion criteria: > 80 years MI; vascular surgery unstable angina or stroke 3 months before the study;
severe hypertension; occlusive thromboangiitis; congenital or acquired haemorrhagic diseases; pregnant
or nursing women
Interventions Treatment: policosanol 10 mg tablets once daily.
Control: lovostatin 20 mg tablets once daily.
Duration: 20 weeks.
Outcomes Primary: initial claudication distance; absolute claudication distance; ABPI.
Secondary: lipid profile and fibrinogen levels.
Side effects: tolerability.
Notes Some patients had hypercholesterolemia.
Biochemical and haematological outcomes measured and recorded pre, during, and post study.
ABPI recorded as ankle/arm pressure ratio of the worst lower limb.
Authors used terms initial (ICD) and absolute claudication distance (ACD). For comparison we used
pain-free and total walking distance.
Authors contacted for additional information on trial. Response received
Risk of bias
Item Authors’ judgement Description
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Castano 2003 (Continued)
Allocation concealment? Yes A - Adequate
Coccheri 2002
Methods Study design: double blind, randomised, placebo-controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not stated.
Exclusions post randomisation: none.
Losses to follow up: sulodexide 17; placebo 34.
Intention to treat: yes.
Participants Country: Italy.
Setting: hospital outpatients.
No: 286 sulodexide 143; placebo 143.
Age: sulodexide 64.7 ± 7.6; placebo 66.2 ± 7.5.
Sex: males, 230 sulodexide 120, placebo 110; females 56, sulodexide 23, placebo 33.
Inclusion criteria: age 45 to 75 years; presence of chronic PAD diagnosed by echo-colour Doppler ul-
trasound; history of intermittent claudication for at least 6 months (no acute deterioration in previous
3 months); maximum walking distance 100 to 300 m, measured by standard treadmill test; repeated
treadmill test after 2 week wash our and run-in period to check stability of claudication; ABPI at rest
measured by Doppler less than or equal to 0.70 on worst leg.
Exclusion criteria: disorders preventing correct performance of treadmill test; abdominal aortic aneursym
> 3 cm; occlusion or severe hamodynamic stenosis of pelvic arteries; history of gangliotomy or surgical
revascularisation of the affected limb; serious endocrine disorders; type I diabetes; severe liver or kidney
function impairment; severe heart disease; malignant arterial hypertension; any form of cancer; inflam-
matory vascular disease; history of hypersensitivity to extractive mucopolysaccharides; need for treatment
with oral anticoagulants, ticlopidine or NSAIDs; pregnant and nursing mothers
Interventions Treatment: sulodexide 60 mg i.m. daily (for 20 days), followed by 100 mg orally (for 6 months).
Control: placebo.
Duration: 27 weeks.
Outcomes Primary: doubling of the baseline pain-free walking distance.
Secondary: doubling the maximal walking distance; pain-free and maximum walking distances
Notes Safety data included. No data on biochemical outcomes.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Corsi 1985
Methods Study design: double blind, randomised, placebo-controlled trial.
Method of randomisation: randomisation list.
Concealment of allocation: key to randomisation list provided by drug company in sealed envelopes.
Exclusions post randomisation: none.
Losses to follow up: none.
Intention to treat: not specifically stated but all patients complied the assingned therapy and completed
Participants Country: Italy.
Setting: hospital.
No: 30, sulodexide 15; placebo 15.
Age: (mean) sulodexide 65.8 ± 11.1; placebo 69.8 ± 12.6.
Sex: sulodexide, males 12, females 3; placebo, males 10, females 5.
Inclusion criteria: stage II peripheral disease (Fontaine’s classification).
Exclusion criteria: patients with diabetic disease, other non-atheromatous vasculopathy, or chronic diseases
Interventions Treatment: sulodexide (300 ULS) one vial twice daily i.m. for 20 days followed by 150 (ULS) 2 capsules
twice daily for 70 days plus hypolipidaemic diet, if indicated.
Control: identical placebo and diet, if indicated.
Duration: 90 days.
Outcomes Primary: pain-free walking distance; ABPI; blood flow; symptoms; side effects.
Secondary: lipid profile and fibrinogen levels.
Notes Biochemical and haematologcial outcomes measured pre, during, and post study.
Active treatment associated with reduced tChol and VLDL.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Cospite 1985
Methods Study design: double blind, randomised, placebo-controlled trial.
Method of randomisation: not stated.
Concealment of allocation: supplied by manufacturer.
Exclusions post randomisation: none.
Losses to follow up: none.
Intention to treat: not stated
Participants Country: Italy.
Setting: hospital outpatient department.
No: 30.
Age: (mean) 58, range 40 to 72 years.
Sex: males 20; females 10.
Inclusion criteria: multi-sited atherosclerosis confirmed by Doppler.
Exclusion criteria: patients with severe liver disease, and severe endocrine dysfunction
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Cospite 1985 (Continued)
Interventions Treatment: one vial of sulodexide (300 LSU) twice daily i.m. for 10 days followed by 2 sulodexide capsules
(150 LSU) twice daily for 80 days.
Control: identical placebo
Duration: 90 days.
Outcomes Total walking distance; subjective parameters (night pain intensity, cramps, tingling, burning, sense of
coldness in lower limbs) confirmed using Doppler.
Subjective parameters were confirmed using Doppler.
Notes Biochemical and haematologcial outcomes measured pre, during, and post study. Active treatment asso-
ciated with reduced tChol and VLDL and increased HDL
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Gans 1990
Methods Study design: double blind, randomised controlled trial.
Method of randomisation: not stated.
Allocation concealment: numbered, sealed envelopes.
Exclusions post randomisation: 3 (2 in treatment group and 1 in placebo group)
Losses to follow up: 2 (1 in each group).
Intention to treat: no.
Participants Country: Netherlands.
Setting: hospital.
No: 37 randomised, 32 completed the trial.
Age: range 18 to 80 years.
Sex: male 22, females 10.
Inclusion criteria: intermittent claudication due to PAD, stable for 1 year according to treadmill and
ABPI.
Exclusion criteria:MI < 3months; unstable angina; poorly controlledDM; CLI; hypertension; fish allergy;
other lipid-lowering treatment; antiplatelet treatment; and other medical disorders
Interventions Treatments: six capsules fish oil daily (1.8 g eicosapentaenoic acod + 1.2 g docosahexaenoic acid).
Control: six capsules corn oil (3 g linoleic acid) daily.
Duration: 4 months.
Outcomes ABPI; walking distance (pain-free and total).
Notes Biochemical and haematologcial outcomes measured pre, during, and post study. Active treatment asso-
ciated with reduced TG and increased HDL
Risk of bias
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Gans 1990 (Continued)
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
HPS
Methods Study design: double blind, placebo-controlled trial ’2 x 2 factorial design’ .
Method of randomisation: central telephone system using minimisation.
Concealment of allocation: centralised.
Exclusions post randomisation: not known (sub group of a large study).
Losses to follow up: not known (sub group of a large study)
Intention to treat: yes.
Participants Country: UK.
Setting: hospital outpatient department.
No: 6748
Age: 40 to 80 years
Sex: (with PAD) males 5014; females 1734.
Inclusion criteria (for thewholeHPS study):men andwomen aged40-80 yearswith non fasting blood total
cholesterol concentrations of at least 3.5 mmol/l (135 mg/dl) were eligible provided they had a medical
history coronary disease, PAD, cerebrovascular disease, diabetes, or treated hypertension (if also male and
aged at least 65 years). PAD was defined as intermittent claudication, any peripheral revascularisation
procedure, or aortic aneurysm.
Exclusion criteria: anyone in whom statin therapy was considered to be clearly indicated; chronic liver
disease; severe renal disease or evidence of impaired renal function; inflammatory muscle disease; concur-
rent treatment with ciclosporin, fibrates or high dose niacin; child bearing potential; severe heart failure
Interventions Treatment: simvastatin 40 mg with or without antioxidant vitamins (650 mg vitamin E, 250 mg vitamin
C, 20 mg beta carotene).
Control: placebo with or without antioxidant vitamins (650 mg vitamin E, 250 mg vitamin C, 20 mg
beta carotene).
Duration: 5 year treatment period.
Outcomes All-causemortality; death due to vascular andnon-vascular causes; non-fatalMI; non-fatal stroke; coronary
or non-coronary revascularisation
Notes Lipid profiles and blood vitamin concentrations. The trial included a wide range of patients at increased
risk of coronary heart disease death (33% had PAD). Active treatment associated with reduced tChol,
LDL and TG and increased HDL
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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LEADER
Methods Study design: double blind, randomised, placebo-controlled trial.
Method of randomisation: not stated.
Method of allocation: trial co-ordinating centre.
Exclusions post randomisation: none.
Losses to follow up: bezafibrate 369 (47.1%); placebo 403 (51.3%).
Intention to treat: yes.
Participants Country: UK.
Setting: 85 general practices and 9 hospital vascular clinics.
No: 1568, bezafibrate 783; placebo: 785.
Age: bezafibrate (mean) 68.4 (SD 8.9); placebo (mean) 68.0 (SD 8.8).
Sex : all male.
Inclusion criteria: lower extremity arterial disease confirmed with the Edinburgh Claudication question-
naire.
Exclusion criteria: Men with PAD were ineligible for the following reasons: unstable angina, unless or
until it was controlled; total serum cholesterol less than 3.5 mmol/l or more than 8.0 mmol/l; significant
renal or hepatic disease; a known hepatitis B or C or HIV positive status; malignant disease (other than
non-melanoma skin cancer) within the past 5 years; they were taking or likely to need lipid-lowering
agents or monamine oxidase inhibitors; they were unlikely to comply with trial treatment or procedures;
they were in another trial; or at the discretion of the general practitioner for other reasons
Interventions Treatment: bezafibrate 400 mg daily.
Control: placebo tablets.
Duration: minimum 3 years, maximum 4 years.
Outcomes Primary: combination of coronary heart disease and/or stroke.
Secondary: all coronary events, fatal and non-fatal coronary events separately, and strokes alone
Notes Haematological and biochemical parameters measured. Active treatment associated with reduced tChol,
LDL and TG and increased HDL
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Liguori 1993
Methods Study design: double blind, double-dummy, randomised, placebo-controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not stated.
Exclusions post randomisation: not stated.
Losses to follow up: withdrawals 22; 1 not recorded.
Intention to treat: not stated.
Participants Country: Italy (mulitcentre).
Setting:inpatients and outpatients.
No: 248 randomised, 225 completed the treatment.
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Liguori 1993 (Continued)
Age: (range in years) treatment, 44 to 93; control, 43 to 93.
Sex: treatment, males 124, females 62; control, males 46, females 16.
Inclusion criteria: PAD (Fontaine stage II or III, confirmed by clinical examination and Doppler test).
Exclusion criteria: Severe systemic infections or severe uncompensated hypertension; active gastroduode-
nal ulcer; recent haemorrhagic stroke; severe neurologic disorders; neoplastic diseases; renal, hepatic, or
cardiovascular failure; known hypoersensitivity to extractive mucopolysaccharides; patients with any risk
of haemorrhage; receiving fibrinolytic or anticoagulant treatment; and pregnant or breastfeeding women
Interventions Treatment: sulodexide, 25 mg capsules twice daily, 50 mg enteric-coated tablets twic daily, or 100 mg
enteric-coated tablets once daily. Patients in the treatment groups received dummy treatment of the two
active treatments not provided for in that particular group.
Control: placebo. Patients received dummy versions of active drug according to the approprioate dosage
schedule.
Duration: 90 days.
Outcomes Doppler analysis, Winsor Index, treadmill test (pain-free walking distance), side effects
Notes Haematological and biochemical analyses performed monthly. Effect on lipids not reported
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Mohler 2003
Methods Study design: double blind, randomised, placebo-controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not stated.
Exclusions post randomisation: 10.
Losses to follow up: none.
Intention to treat: no.
Participants Country: USA.
Setting: hospital outpatients.
No: 354.
Age: (mean) treatment (group 1) 69; (group 2) 68; control 67.
Sex: males 273, treatment (group 1) 90, (group 2) 95, control 88; females 81 treatment (group 1) 30,
(group 2) 25, control 26.
Inclusion criteria: > 25 years; stable intermittent claudication for longer than 6 months; able to complete
screening treadmill test; LDL less than or equal to 160 mg/dl (4.14 mmol/l.
Exclusion criteria: MI; coronary revascularization; peripheral vascular surgery; percutaneous intervention
procedure within 6 months; unstable angina within previous 3 months; stroke or TIA within 6 months;
DVT within previous 3 months
Interventions Treatment: atorvastatin (group1)10 mg daily; (group 2) 80 mg daily.
Control: placebo.
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Mohler 2003 (Continued)
Duration: 12 months.
Outcomes Primary: change in maximal walking time at 12 months.
Secondary: change from baseline in pain-free walking time, or community-based functional status by the
SF-36, WIQ, and LOPAR quality of life questionnaires, or ABPI; incidence of peripheral vascular e.g.
worsening symtoms of claudication, development of rest ischaemia, peripheral revascularisation procedure,
or limb amputation, or critical cardiovascular events e.g. MI, stroke and vascular death; lipid profiles
Notes Biochemical parameters measured at baseline and after 12 months. Active treatment associated with
reduced tChol, LDL and TG and increased HDL
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Mondillo 2003
Methods Study design: double blind, randomised, placebo-controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not stated.
Exclusions post randomisation: none.
Losses to follow up: none.
Intention to treat: not stated but all patients complied with assigned treatment, completed and analysed
Participants Country: Italy
Settting: hospital outpatients.
No: 86.
Age: (mean) simvastatin 67 ± 6; placebo 67 ± 7.
Sex: males 61; females 25.
Inclusion criteria: symptomatic PAD; intermittent claudication; pain free at rest for at least 12 months;
ultransonographic or angiographic evidence of obstructive PVD (i.e. arterial stenosis >50% in both lower
limbs within previous 4 months); resting systolic ABPI less than or equal to 0.9; serum cholesterol level
> 220 mg/dl; written informed consent.
Exclusion criteria: previous surgery or angioplasty for PAD; >40% change in pain-free walking distance in
previous 2 months; renal or liver disease; any type of cancer or autoimmune disease; conditions that could
limit ability to perform an exercise test; hyperthyroidism or hypothyroidism; uncontrolled hypertension;
history of acute coronary syndromes or stroke within the previous 6 months; previous treatment with
statins or other cholesterol-lowering drugs
Interventions Treatment: simvastatin 40 mg daily.
Control: placebo.
Duration: 6 months.
Outcomes Pain-free walking distance; total walking distance; ABPI; blood pressure; lipid profile and biochemical
tests; claudication self-assessement questionnaire
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Mondillo 2003 (Continued)
Notes Biochemical parameters measured pre, during, and at end of study. Active treatment associated with
reduced tChol, LDL and TG and increased HDL
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Nye 1973
Methods Study design: double blind, randomised, placebo-controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not stated.
Exclusions post randomisation: none. Drop outs 22.
Losses to follow up: none.
Intention to treat: not evident from result and not stated
Participants Country: New Zealand.
Setting: hospital.
No: 68 randomised.
Age: 40 to 74 years.
Sex: male 64; female 4.
Inclusion criteria: PAD of aorta or lower limb vessels (new referrals or those with previous surgery).
Exclusions: DM and multiple drug therapy.
Interventions Treatment: betapyridyl carbinol up to 1.8 g plus advice (anti-smoking, weight loss and exercise).
Control: identical placebo plus advice.
Duration: 2 yr.
Outcomes Mortality; walking distance; symptoms; side effects.
Notes Biochemical parameters measured pre, during, and at end of study. Active treatment associated with
reduced tChol.
Two male patients developed liver toxicity while on Betapyridyl carbinol
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Palmieri 1984
Methods Study design: double blind, randomised, placebo-controlled trial.
Method of randomisation: not stated.
Concealment of allocation: not stated.
Exclusions post randomisation: none.
Losses to follow up: none.
Intention to treat: no (randomised 30 but analysed only 22 for interested outcome)
Participants Country: Italy.
Setting: hospital outpatients.
No: 30.
Age: 20 to 60 years (mean) 42.5 ± 8.27.
Sex: males 16; females 14.
Inclusion criteria: PAD (Leriche’s stages I-II) confirmed by Doppler, plethysmography and ultrasonogra-
phy.
Exclusion criteria: not stated.
Interventions Treatment: sulodexide 600 units daily i.m. followed by oral treatment.
Control: placebo i.m. followed by oral treatment.
Duration: 20 days (i.m.) followed by 70 days oral treatment.
Outcomes Primary: pain-free walking distance. At rest oscillometric index
Notes Some patients had hyperliporoteinaemia.
Biochemical and haematological outcomes measured pre and post study. Active treatment associated with
reduced TG
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
PQRST
Methods Study design: double blind, randomised, placebo-controlled trial. Stratified randomisation by risk, sex
and city.
Method of randomisation: not stated.
Concealment of allocation: not stated.
Exclusions post randomisation: 29 patients were excluded because of inadequate primary endpoint mea-
surements.
Losses to follow up: none.
Intention to treat: no.
Participants Country: Sweden.
Setting: hospital.
No: 303 randomised, 274 analysed.
Age: < 71 years.
Sex: males 158; females 116.
Inclusion criteria: PAD on angiogram; hypercholesterolaemia (tChol > 265 mg/dl, LDL > 175 mg/dl,
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PQRST (Continued)
and TG < 350 mg/dl) and those who responded to lipid-lowering drugs.
Exclusion criteria: Type III hyperlipidaemia; DM, MI < 6 months; unstable angina; hypertension; and
other medical disorders
Interventions Treatment: probucol 1g, cholestyramine 8 to 16 g plus diet (P:S ratio 0.5).
Control: identical placebo, cholestyramine 8 to 16 g plus diet as above.
Duration: 3 years.
Outcomes Mortality; non-fatal events; angiography (atheroma volume, edge roughness and minimal width); ABPI;
walking distance; side effects
Notes Total cholesterol significantly lower in treated than control group at end of trial. Significant reduction in
HDL cholesterol in treatment group
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
St Thomas’ Trial
Methods Study design: randomised controlled trial. Outcome assessors blind.
Method of randomisation: not stated
Concealment of allocation: not stated.
Exclusions post randomisation: 1 patient from the treatment group withdrawn due to .
Losses to follow up: no losses stated.
Intention to treat: no (did not count one excluded patient)
Participants Country: England.
Setting: hospital.
No: 25 randomised, 24 analysed.
Age: < 65 years, (mean) treatment 54.8; control 56.1.
Sex: males 21; females 3.
Inclusion criteria: stable intermittent claudication > 6 months (due to femoro-popliteal disease), and
hyperlipidaemia (tChol > 6.5 mmol/l and TG >1.8 mmol/l, or both).
Exclusions: imminent surgery; secondary hyperlipidaemia;DM;hypertension; andothermedical disorders
Interventions Treatment: depended on type of hyperlipidaemia (II - cholestyramine 12 to 24 g plus nicotinic acid 3 to
6 g, if required; III - clofibrate 1.5 to 2 g; IV - nicotinic acid 3 to 6 g) plus “usual care”
Control: “usual care” (anti-smoking and weight-loss advice).
Duration: (mean) 19 months.
Outcomes Angiography (visual assessment and edge irregularity index, per segment)
Notes Total cholesterol significantly lower in treated than control group at end of trial. Active treatment also
associated with reduced TG and increased HDL
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St Thomas’ Trial (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
ABPI: ankle brachial pressure index
ACD: absolute claudication distance
CABG: coronary artery bypass graft
CLI: critical limb ischaemia
DM: diabetes mellitus
DP: dorsalis pedis
DVT: deep vein thrombosis
HDL: high density lipoprotein
ICD: inital claudication distance
i.m.: intramuscular
LDL: low density lipoprotein cholesterol
LEAD: lower extremity arterial disease
LRU: lipoproteinlipase releasing units
MI: myocardial infarction
NSAID: non steroidal anti-inflammatory
PAD: peripheral arterial disease
PT: posterior tibial
PVD: peripheral vascular disease
tChol total cholesterol
TG: triglycerides
TIA: transient ischaemic attack
VAS: visual analogue score
VLDL: very low density lipoprotein
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ADMIT Randomised controlled trial. No relevant clinical outcomes.
Aguilera 2004 Randomised controlled trial. No relevant clinical outcomes.
Altmann 1986 Double blind controlled clinical trial of pentoxifylline versus xantinol nicotinate
Aronow 2003 Randomised controlled trial. No relevant outcomes.
Attanasio 2001 Randomised controlled trial. Patients randomised to Simvastatin or Atorvastatin. Cost effectiveness to
determine annual maintenance costs of reducing LDL-C in hypercholesterolemic patients. No relevant
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clinical outcomes
Bartolo 1984 Double blind, randomised controlled trial. Excluded due to study design. Treatment group received su-
lodexide parenterally for 20 days and the control group received placebo parenterally for 20 days; both
groups then received oral sulodexide for 70 days
Berrettini 1996 Double blind randomised controlled study of eicosapentaenoic acid and docosahexaenoic acid versus corn
oil. No relevant outcomes
Betteridge 1999 Double blind, randomised controlled trial. No relevant clinical outcomes
Blann 2001 Double blind, randomised controlled trial of cerivastatin versus simvastatin. No relevant clinical outcomes
Bonanno 1985 Double blind, randomised controlled trial. Excluded due to study design. Treatment group received su-
lodexide parenterally for 20 days and the control group received placebo parenterally for 20 days; both
groups then received oral sulodexide for 70 days
Broome 1967 Double blind, randomised controlled trial. No relevant outcome measures. Measured blood flow
Brown 1998 Randomised controlled trial. No clinical outcomes measures.
Calabro 1985 Controlled clinical trial.
Castano 2004 Double blind, randomised controlled trial. Control group received antiplatelet therapy
Castelluccio 1991 Double blind, randomised controlled trial. No relevant outcomes
Catania 1992 Double blind, randomised controlled trial. No relevant outcomes
Ciuffetti 1989 Double blind, randomised controlled trial. No relevant outcomes
CLAS Randomised controlled trial. Participants included not only those suffering from lower limb atherosclerosis
but also unaffected subjects
Coffman 1983 Randomised controlled trial. Patients with hyperlipoproteinaemia were given diet and/or Clofibrate. No
relevant outcomes. Circulation tests and lipid levels measured
Crepaldi 1986 Double blind, randomised controlled trial. No relevant outcomes
Crepaldi 1990 Double blind, randomised controlled trial. No relevant outcomes
Davis 1975 Double blind, randomised controlled trial. No relevant outcomes
Fischer 1980 This double blind, randomised cross-over trial of clofibrate vs placebo in patients with peripheral arterial
disease was excluded for the following reasons: unrealistically short follow-up period (6 weeks); no clinical
outcome measures; and only 10 patients in each group with a mixed pattern of disease
Gallino 2004 Randomised controlled trial of patients post femoropopliteal angioplasty
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Giansante 1990 Double blind, randomised study of xanthinol nicotinate versus antiplatelet agents did not have any relevant
clinical outcomes
Head 1986 Double blind, randomised controlled trial. Uncertain lipid-lowering property of inositol nicotinate. No
relevant outcomes
Heller 1989 Randomised controlled trial. No relevant clinical outcome measures
Hentzer 1967 Double blind, randomised controlled trial. Uncertain lipid-lowering property of inositol nicotinate
Hutchinson 1983 Double blind, randomised controlled trial comparing two different lipid-lowering diets, and therefore it
does not have an adequate control group
Ito 2001 Randomised controlled trial. All participants received pravastatin. Only 5 patients with PAOD
Kiff 1988 Double blind, randomised controlled trial. Uncertain lipid-owering property of inositol nicotinate
Kirk 1999 Double blind, randomised controlled trial. No clinical outcome measures
Kissin 1951 Double blind, randomised controlled trial. Only one single dose given
Larsen 1969 Double blind, controlled clinical trial.
Leng 1998b This was a 2 year randomised controlled trial of gamma-linolenic acid and eicosapenataenoic acid in 120
patients with intermittent claudication. The sample size was calculated on the assumption that treatment
with these polyunsaturated fatty acids would reduce cholesterol levels, but during the trial was there was no
reduction in plasma cholesterol. Indeed, both treatment and control groups demonstrated an increase in
lipid levels during the trial. This study could not therefore be included in a review of lipid-lowering therapy
Lunetta 1992 Double blind randomised controlled cross over trial of Sulodexide versus placebo. No relevant outcomes.
Blood viscosity and plasma fibrinogen concentrations measured
Marzola 1985 Double blind, randomised controlled trial. No relevant outcomes
Maxwell 2000 Double blind, randomised controlled trial. Dietary study not a lipid-lowering treatment
Mori 1992 Double blind randomised controlled study of fish oil versus olive oil. No relevant outcomes
O’Hara 1988 Double blind, randomised controlled trial. Uncertain lipid-lowering property of inositol nicotinate
Oxford Cholesterol Randomised placebo controlled trial. Study of the effect of simvastatin on haemostatic variables. No relevant
clinical outcomes
Palmieri 1982 Double blind, randomised controlled trial. No relevant outcomes
Palmieri 1987 Double blind, randomised controlled trial. No relevant outcomes
Perego 1981 Double blind, randomised controlled trial. No relevant outcomes
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Pisano 1986 Double blind, randomised controlled trial. No relevant outcomes
Ramirez-Tortosa 1999 Randomised controlled trial. No relevant outcomes.
Ramírez-Tortosa 1999 Randomised controlled trial. No relevant outcomes.
Saunders 2000 Double blind, randomised controlled trial. No relevant outcomes
Schumer 1963 Double blind, randomised controlled trial. A single short report represents the only available results from
this trial. Contact with the author confirmed it was randomised, but into two very unequal groups sug-
gesting probable bias. In addition, the mode of action of gallogen is unclear, and although it is probably
hypolipidaemic, lipid levels were not measured in this trial
Shustov 1997 Randomised controlled trial comparing the therapeutic efficacy of sulodexide versus pentoxifylline
Smith 1981 Double blind, randomised controlled trial. Muscle blood flow and skin temperature measured in six patients
Smith 1999 Double blind, randomised controlled trial. Cost analysis. Hypercholesterolaemic patients randomised to
atorvastatin, fluvastatin, pravastatin or simvastatin. Lipid values measured every six weeks to ensure that
LDL-C target achieved
Tyson 1979 Double blind, controlled clinical trial. Outcomes included walking rate in paces/minute, pain and pulse
scores
LDL-C = low density lioprotein cholesterol
Characteristics of studies awaiting assessment [ordered by study ID]
Borreani 1993
Methods Randomised double-blinded trial.
Participants Chronic peripheral arterial occlusive disease; n = 100.
Interventions Sulodexide versus placebo.
Outcomes 1. Pain-free walking distance
2. Maximum walking distance
3. Activated partial thromboplstin time
4. Fibrinogen levels
5. Platelet count
Notes Requires further translation.
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Degni 1973
Methods Article is coded as a randomised controlled trial in CENTRAL. Abstract states double-blind, cross-over study
Participants Patients with chronic obstructive atherosclerosis of the lower extremities; n = 20
Interventions ER-113V (each capsule containing pyridinolcarvamate - 160 mg and nicotinic acid - 70 mg, 6 capsules daily
Outcomes 1. Paresthesias
2. Sensation of cold
3. Intermittent claudication
4. Cutaneous temperature
5. Oscillometry
6. Necrotic ulcer
Notes Unable to obtain a copy
Di Stefano 1984
Methods Double-blinded study. Title suggest that this is a controlled clinical trial. Unable to ascertain if this is a randomised
trial
Participants 30 participants suffering from peripheral arterial occlusive disease of the lower limbs: treatment group 15; control
group 15
Interventions Sulodexide i.m 20 days followed by oral dose for 70 days versus placebo
Outcomes Biochemical outcomes: triglycerides, HDL; oscillographic and photoplethysmographic tests of the lower limb
Notes Unable to get copy. Details taken from abstract in EMBASE
Mayer 2001
Methods Article is coded as a randomised controlled trial in MEDLINE
Participants Arterial occlusion of the lower extremities; n = 50.
Interventions Statins (simvastatin) versus diet.
Outcomes “Claudication interval”.
Notes Original article is in Czechoslovakian. Requires translation
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D A T A A N D A N A L Y S E S
Comparison 1. Any lipid-lowering regimen vs control: all trials
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 6 Odds Ratio (M-H, Random, 95% CI) Subtotals only
1.1 All-cause mortality: All
studies
6 2388 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.49, 1.50]
1.2 All-cause mortality
without PQRST
5 2085 Odds Ratio (M-H, Random, 95% CI) 0.92 [0.54, 1.57]
1.3 All-cause mortality
without studies with moderate
or high risk of bias
3 1685 Odds Ratio (M-H, Random, 95% CI) 0.84 [0.36, 1.96]
1.4 All-cause mortality
(Policosanol)
2 118 Odds Ratio (M-H, Random, 95% CI) 0.19 [0.02, 1.71]
2 Total cardiovascular events 8 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Total cardiovascular - All
studies
8 9423 Odds Ratio (M-H, Random, 95% CI) 0.80 [0.59, 1.08]
2.2 Total cardiovascular
without PQRST
7 9120 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.55, 0.98]
2.3 Total cardiovascular events
without studies with moderate
or high risk of bias
4 8434 Odds Ratio (M-H, Random, 95% CI) 0.76 [0.54, 1.07]
2.4 Total cardiovascular
(HMG Co A Group / Statins)
2 7102 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.67, 0.82]
2.5 Total cardiovascular events
(Policosanol group)
2 118 Odds Ratio (M-H, Random, 95% CI) 0.06 [0.01, 0.46]
3 Fatal cardiovascular 6 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Fatal cardiovascular: All
studies
6 2321 Odds Ratio (M-H, Random, 95% CI) 0.96 [0.70, 1.33]
3.2 Fatal cardiovascular
without PQRST
5 2018 Odds Ratio (M-H, Random, 95% CI) 0.97 [0.70, 1.35]
3.3 Fatal cardiovascular
without studies with moderate
or high risk of bias
3 1686 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.73, 1.43]
3.4 Fatal cardiovascular
(Policosanol group)
2 118 Odds Ratio (M-H, Random, 95% CI) 0.33 [0.03, 3.30]
4 Non-fatal cardiovascular events 7 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Non-fatal cardiovascular:
All studies
7 2675 Odds Ratio (M-H, Random, 95% CI) 0.80 [0.48, 1.34]
4.2 Non-fatal cardiovascular
without PQRST
6 2372 Odds Ratio (M-H, Random, 95% CI) 0.64 [0.36, 1.13]
4.3 Non-fatal cardiovascular
without studies with moderate
or low risk of bias
3 1686 Odds Ratio (M-H, Random, 95% CI) 0.25 [0.03, 1.83]
4.4 Non-fatal cardiovascular
(Policosanol group)
2 118 Odds Ratio (M-H, Random, 95% CI) 0.07 [0.01, 0.56]
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5 Total coronary 8 Odds Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Total coronary: All studies 8 9424 Odds Ratio (M-H, Random, 95% CI) 0.80 [0.66, 0.96]
5.2 Total cornary without
PQRST
7 9120 Odds Ratio (M-H, Random, 95% CI) 0.76 [0.67, 0.87]
5.3 Total coronary excluding
studies with moderate or high
risk of bias
4 8434 Odds Ratio (M-H, Random, 95% CI) 0.76 [0.67, 0.87]
5.4 Total coronary (HMG Co
A Group / Statins)
2 7102 Odds Ratio (M-H, Random, 95% CI) 0.77 [0.66, 0.89]
5.5 Total coronary
(Policosanol group)
2 118 Odds Ratio (M-H, Random, 95% CI) 0.20 [0.02, 1.85]
6 Fatal coronary event 5 Odds Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Fatal coronary: All studies 5 2557 Odds Ratio (M-H, Random, 95% CI) 0.94 [0.66, 1.33]
6.2 Fatal coronary without
PQRST
4 2254 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.67, 1.34]
7 Non-fatal coronary event 6 Odds Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Non-fatal coronary: All
studies
6 2629 Odds Ratio (M-H, Random, 95% CI) 0.73 [0.37, 1.45]
7.2 Non-fatal coronary
without PQRST
5 2326 Odds Ratio (M-H, Random, 95% CI) 0.54 [0.34, 0.86]
7.3 Non-fatal coroanry
excluding studies with
moderate or high risk of bias
3 1686 Odds Ratio (M-H, Random, 95% CI) 0.53 [0.33, 0.85]
7.4 Non-fatal coronary
(Policosanol group)
2 118 Odds Ratio (M-H, Random, 95% CI) 0.20 [0.02, 1.85]
8 Total stroke 6 Odds Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Total stroke: All studies 6 9074 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.58, 1.33]
8.2 Total stroke excluding
studies with moderate or high
risk of bias
4 8434 Odds Ratio (M-H, Random, 95% CI) 0.86 [0.52, 1.41]
8.3 Total stroke (HMG Co A
Group / Statins)
2 7102 Odds Ratio (M-H, Random, 95% CI) 0.72 [0.59, 0.88]
8.4 Total stroke (Policosanol
group)
2 118 Odds Ratio (M-H, Random, 95% CI) 0.19 [0.02, 1.71]
9 Fatal stroke 5 Odds Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Fatal stroke: All studies 5 2326 Odds Ratio (M-H, Random, 95% CI) 1.14 [0.54, 2.43]
9.2 Fatal stroke excluding
studies with moderate or high
risk of bias
3 1686 Odds Ratio (M-H, Random, 95% CI) 1.22 [0.55, 2.71]
9.3 Fatal stroke (Policosanol
group)
2 118 Odds Ratio (M-H, Random, 95% CI) 0.33 [0.03, 3.30]
10 Non-fatal stroke 5 Odds Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Non-fatal stroke: All
studies
5 2326 Odds Ratio (M-H, Random, 95% CI) 1.16 [0.76, 1.77]
10.2 Non-fatal stroke without
studies with moderate or high
risk of bias
3 1686 Odds Ratio (M-H, Random, 95% CI) 1.14 [0.74, 1.74]
10.3 Non-fatal stroke
(Policosanol group)
2 118 Odds Ratio (M-H, Random, 95% CI) 0.33 [0.03, 3.30]
11 Revascularization (HMG Co A
Group / Statins)
2 7102 Odds Ratio (M-H, Random, 95% CI) 0.73 [0.64, 0.83]
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12 Pain-free walking distance
(PFWD)
7 Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 PFWD: All studies 7 317 Mean Difference (IV, Random, 95% CI) 89.76 [30.05, 149.
47]
12.2 PFWD (Policosanol
group)
2 118 Mean Difference (IV, Random, 95% CI) 131.80 [14.97, 248.
64]
12.3 PFWD (Sulodexide) 3 81 Mean Difference (IV, Random, 95% CI) 94.15 [-5.33, 193.
62]
13 Total walking distance (TWD) 4 Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 TWD: All studies 4 236 Mean Difference (IV, Random, 95% CI) 152.00 [32.11, 271.
88]
13.2 TWD (Policosanol
group)
2 118 Mean Difference (IV, Random, 95% CI) 274.48 [9.21, 539.
74]
14 Ankle brachial index (ABI) 6 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 ABI: All studies 6 620 Mean Difference (IV, Random, 95% CI) 0.04 [-0.01, 0.09]
14.2 ABI (Policosanol group) 2 118 Mean Difference (IV, Random, 95% CI) 0.07 [-0.05, 0.18]
14.3 ABI (HMG Co A Group
/ Statins)
2 440 Mean Difference (IV, Random, 95% CI) 0.05 [-0.03, 0.13]
Analysis 1.1. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 1 All-cause mortality.
Review: Lipid-lowering for peripheral arterial disease of the lower limb
Comparison: 1 Any lipid-lowering regimen vs control: all trials
Outcome: 1 All-cause mortality
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 All-cause mortality: All studies
Castano 1999 0/31 2/31 0.5 % 0.19 [ 0.01, 4.07 ]
Castano 2001 0/27 2/29 0.5 % 0.20 [ 0.01, 4.36 ]
LEADER 204/783 195/784 95.8 % 1.06 [ 0.85, 1.34 ]
Mohler 2003 5/240 1/114 1.1 % 2.40 [ 0.28, 20.82 ]
Nye 1973 2/23 5/23 1.6 % 0.34 [ 0.06, 1.99 ]
PQRST 0/152 2/151 0.5 % 0.20 [ 0.01, 4.12 ]
Subtotal (95% CI) 1256 1132 100.0 % 0.86 [ 0.49, 1.50 ]
Total events: 211 (Treatment), 207 (Control)
Heterogeneity: Tau2 = 0.09; Chi2 = 5.59, df = 5 (P = 0.35); I2 =11%
Test for overall effect: Z = 0.53 (P = 0.60)
2 All-cause mortality without PQRST
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
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(. . . Continued)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Castano 1999 0/31 2/31 0.5 % 0.19 [ 0.01, 4.07 ]
Castano 2001 0/27 2/29 0.5 % 0.20 [ 0.01, 4.36 ]
LEADER 204/783 195/784 96.3 % 1.06 [ 0.85, 1.34 ]
Mohler 2003 5/240 1/114 1.1 % 2.40 [ 0.28, 20.82 ]
Nye 1973 2/23 5/23 1.6 % 0.34 [ 0.06, 1.99 ]
Subtotal (95% CI) 1104 981 100.0 % 0.92 [ 0.54, 1.57 ]
Total events: 211 (Treatment), 205 (Control)
Heterogeneity: Tau2 = 0.08; Chi2 = 4.45, df = 4 (P = 0.35); I2 =10%
Test for overall effect: Z = 0.31 (P = 0.75)
3 All-cause mortality without studies with moderate or high risk of bias
Castano 1999 0/31 2/31 0.5 % 0.19 [ 0.01, 4.07 ]
Castano 2001 0/27 2/29 0.5 % 0.20 [ 0.01, 4.36 ]
LEADER 204/783 195/784 98.9 % 1.06 [ 0.85, 1.34 ]
Subtotal (95% CI) 841 844 100.0 % 0.84 [ 0.36, 1.96 ]
Total events: 204 (Treatment), 199 (Control)
Heterogeneity: Tau2 = 0.21; Chi2 = 2.33, df = 2 (P = 0.31); I2 =14%
Test for overall effect: Z = 0.41 (P = 0.68)
4 All-cause mortality (Policosanol)
Castano 1999 0/31 2/31 50.1 % 0.19 [ 0.01, 4.07 ]
Castano 2001 0/27 2/29 49.9 % 0.20 [ 0.01, 4.36 ]
Subtotal (95% CI) 58 60 100.0 % 0.19 [ 0.02, 1.71 ]
Total events: 0 (Treatment), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
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Analysis 1.2. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 2 Total cardiovascular
events.
Review: Lipid-lowering for peripheral arterial disease of the lower limb
Comparison: 1 Any lipid-lowering regimen vs control: all trials
Outcome: 2 Total cardiovascular events
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Total cardiovascular - All studies
Castano 1999 0/31 6/31 0.4 % 0.06 [ 0.00, 1.16 ]
Castano 2001 0/27 7/29 0.4 % 0.05 [ 0.00, 1.01 ]
Coccheri 2002 3/143 9/143 2.0 % 0.32 [ 0.08, 1.20 ]
HPS 895/3384 1101/3364 52.8 % 0.74 [ 0.67, 0.82 ]
LEADER 150/783 160/785 30.3 % 0.93 [ 0.72, 1.19 ]
Mohler 2003 10/240 6/114 3.2 % 0.78 [ 0.28, 2.21 ]
Nye 1973 1/23 3/23 0.7 % 0.30 [ 0.03, 3.15 ]
PQRST 38/152 29/151 10.2 % 1.40 [ 0.81, 2.42 ]
Subtotal (95% CI) 4783 4640 100.0 % 0.80 [ 0.59, 1.08 ]
Total events: 1097 (Treatment), 1321 (Control)
Heterogeneity: Tau2 = 0.06; Chi2 = 15.65, df = 7 (P = 0.03); I2 =55%
Test for overall effect: Z = 1.46 (P = 0.14)
2 Total cardiovascular without PQRST
Castano 1999 0/31 6/31 0.5 % 0.06 [ 0.00, 1.16 ]
Castano 2001 0/27 7/29 0.5 % 0.05 [ 0.00, 1.01 ]
Coccheri 2002 3/143 9/143 2.2 % 0.32 [ 0.08, 1.20 ]
HPS 895/3384 1101/3364 58.7 % 0.74 [ 0.67, 0.82 ]
LEADER 150/783 160/785 33.7 % 0.93 [ 0.72, 1.19 ]
Mohler 2003 11/240 6/114 3.7 % 0.86 [ 0.31, 2.40 ]
Nye 1973 1/23 3/23 0.7 % 0.30 [ 0.03, 3.15 ]
Subtotal (95% CI) 4631 4489 100.0 % 0.74 [ 0.55, 0.98 ]
Total events: 1060 (Treatment), 1292 (Control)
Heterogeneity: Tau2 = 0.04; Chi2 = 10.95, df = 6 (P = 0.09); I2 =45%
Test for overall effect: Z = 2.08 (P = 0.038)
3 Total cardiovascular events without studies with moderate or high risk of bias
Castano 1999 0/31 6/31 0.5 % 0.06 [ 0.00, 1.16 ]
Castano 2001 0/27 7/29 0.5 % 0.05 [ 0.00, 1.01 ]
0.001 0.01 0.1 1 10 100 1000
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Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
HPS 895/3384 1101/3364 62.9 % 0.74 [ 0.67, 0.82 ]
LEADER 150/783 160/785 36.1 % 0.93 [ 0.72, 1.19 ]
Subtotal (95% CI) 4225 4209 100.0 % 0.76 [ 0.54, 1.07 ]
Total events: 1045 (Treatment), 1274 (Control)
Heterogeneity: Tau2 = 0.05; Chi2 = 8.66, df = 3 (P = 0.03); I2 =65%
Test for overall effect: Z = 1.57 (P = 0.12)
4 Total cardiovascular (HMG Co A Group / Statins)
HPS 895/3384 1101/3364 94.1 % 0.74 [ 0.67, 0.82 ]
Mohler 2003 11/240 6/114 5.9 % 0.86 [ 0.31, 2.40 ]
Subtotal (95% CI) 3624 3478 100.0 % 0.74 [ 0.67, 0.82 ]
Total events: 906 (Treatment), 1107 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 5.64 (P < 0.00001)
5 Total cardiovascular events (Policosanol group)
Castano 1999 0/31 6/31 49.9 % 0.06 [ 0.00, 1.16 ]
Castano 2001 0/27 7/29 50.1 % 0.05 [ 0.00, 1.01 ]
Subtotal (95% CI) 58 60 100.0 % 0.06 [ 0.01, 0.46 ]
Total events: 0 (Treatment), 13 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 2.70 (P = 0.0070)
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Analysis 1.3. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 3 Fatal cardiovascular.
Review: Lipid-lowering for peripheral arterial disease of the lower limb
Comparison: 1 Any lipid-lowering regimen vs control: all trials
Outcome: 3 Fatal cardiovascular
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fatal cardiovascular: All studies
Castano 1999 0/31 1/31 1.0 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 1/29 1.0 % 0.35 [ 0.01, 8.85 ]
Coccheri 2002 1/143 4/143 2.2 % 0.24 [ 0.03, 2.22 ]
LEADER 77/783 74/785 93.7 % 1.05 [ 0.75, 1.47 ]
Nye 1973 0/23 2/23 1.1 % 0.18 [ 0.01, 4.03 ]
PQRST 0/152 1/151 1.0 % 0.33 [ 0.01, 8.14 ]
Subtotal (95% CI) 1159 1162 100.0 % 0.96 [ 0.70, 1.33 ]
Total events: 78 (Treatment), 83 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.11, df = 5 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.81)
2 Fatal cardiovascular without PQRST
Castano 1999 0/31 1/31 1.0 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 1/29 1.0 % 0.35 [ 0.01, 8.85 ]
Coccheri 2002 1/143 4/143 2.2 % 0.24 [ 0.03, 2.22 ]
LEADER 77/783 74/785 94.7 % 1.05 [ 0.75, 1.47 ]
Nye 1973 0/23 2/23 1.1 % 0.18 [ 0.01, 4.03 ]
Subtotal (95% CI) 1007 1011 100.0 % 0.97 [ 0.70, 1.35 ]
Total events: 78 (Treatment), 82 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 3.67, df = 4 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.87)
3 Fatal cardiovascular without studies with moderate or high risk of bias
Castano 1999 0/31 1/31 1.1 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 1/29 1.0 % 0.35 [ 0.01, 8.85 ]
LEADER 77/783 74/785 97.9 % 1.05 [ 0.75, 1.47 ]
Subtotal (95% CI) 841 845 100.0 % 1.02 [ 0.73, 1.43 ]
Total events: 77 (Treatment), 76 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.89)
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Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
4 Fatal cardiovascular (Policosanol group)
Castano 1999 0/31 1/31 50.1 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 1/29 49.9 % 0.35 [ 0.01, 8.85 ]
Subtotal (95% CI) 58 60 100.0 % 0.33 [ 0.03, 3.30 ]
Total events: 0 (Treatment), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.4. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 4 Non-fatal
cardiovascular events.
Review: Lipid-lowering for peripheral arterial disease of the lower limb
Comparison: 1 Any lipid-lowering regimen vs control: all trials
Outcome: 4 Non-fatal cardiovascular events
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Non-fatal cardiovascular: All studies
Castano 1999 0/31 5/31 2.4 % 0.08 [ 0.00, 1.45 ]
Castano 2001 0/27 6/29 2.4 % 0.07 [ 0.00, 1.23 ]
Coccheri 2002 2/143 5/143 7.0 % 0.39 [ 0.07, 2.05 ]
LEADER 73/783 86/785 42.1 % 0.84 [ 0.60, 1.16 ]
Mohler 2003 8/240 5/114 12.8 % 0.75 [ 0.24, 2.35 ]
Nye 1973 1/23 1/23 2.6 % 1.00 [ 0.06, 17.02 ]
PQRST 38/152 28/151 30.7 % 1.46 [ 0.84, 2.54 ]
Subtotal (95% CI) 1399 1276 100.0 % 0.80 [ 0.48, 1.34 ]
Total events: 122 (Treatment), 136 (Control)
Heterogeneity: Tau2 = 0.15; Chi2 = 10.16, df = 6 (P = 0.12); I2 =41%
Test for overall effect: Z = 0.85 (P = 0.40)
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Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
2 Non-fatal cardiovascular without PQRST
Castano 1999 0/31 5/31 3.5 % 0.08 [ 0.00, 1.45 ]
Castano 2001 0/27 6/29 3.5 % 0.07 [ 0.00, 1.23 ]
Coccheri 2002 2/143 5/143 10.0 % 0.39 [ 0.07, 2.05 ]
LEADER 73/783 86/785 60.7 % 0.84 [ 0.60, 1.16 ]
Mohler 2003 8/240 5/114 18.5 % 0.75 [ 0.24, 2.35 ]
Nye 1973 1/23 1/23 3.7 % 1.00 [ 0.06, 17.02 ]
Subtotal (95% CI) 1247 1125 100.0 % 0.64 [ 0.36, 1.13 ]
Total events: 84 (Treatment), 108 (Control)
Heterogeneity: Tau2 = 0.11; Chi2 = 6.14, df = 5 (P = 0.29); I2 =19%
Test for overall effect: Z = 1.54 (P = 0.12)
3 Non-fatal cardiovascular without studies with moderate or low risk of bias
Castano 1999 0/31 5/31 5.2 % 0.08 [ 0.00, 1.45 ]
Castano 2001 0/27 6/29 5.2 % 0.07 [ 0.00, 1.23 ]
LEADER 73/783 86/785 89.6 % 0.84 [ 0.60, 1.16 ]
Subtotal (95% CI) 841 845 100.0 % 0.25 [ 0.03, 1.83 ]
Total events: 73 (Treatment), 97 (Control)
Heterogeneity: Tau2 = 1.98; Chi2 = 5.46, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 1.36 (P = 0.17)
4 Non-fatal cardiovascular (Policosanol group)
Castano 1999 0/31 5/31 49.8 % 0.08 [ 0.00, 1.45 ]
Castano 2001 0/27 6/29 50.2 % 0.07 [ 0.00, 1.23 ]
Subtotal (95% CI) 58 60 100.0 % 0.07 [ 0.01, 0.56 ]
Total events: 0 (Treatment), 11 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 2.50 (P = 0.012)
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Analysis 1.5. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 5 Total coronary.
Review: Lipid-lowering for peripheral arterial disease of the lower limb
Comparison: 1 Any lipid-lowering regimen vs control: all trials
Outcome: 5 Total coronary
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Total coronary: All studies
Castano 1999 0/31 1/31 0.2 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 3/29 0.2 % 0.14 [ 0.01, 2.80 ]
Coccheri 2002 1/143 6/143 0.4 % 0.16 [ 0.02, 1.35 ]
HPS 369/3384 465/3364 75.7 % 0.76 [ 0.66, 0.88 ]
LEADER 90/783 111/785 18.2 % 0.79 [ 0.59, 1.06 ]
Mohler 2003 7/240 3/114 0.9 % 1.11 [ 0.28, 4.38 ]
Nye 1973 0/23 1/23 0.2 % 0.32 [ 0.01, 8.25 ]
PQRST 29/152 22/152 4.4 % 1.39 [ 0.76, 2.56 ]
Subtotal (95% CI) 4783 4641 100.0 % 0.80 [ 0.66, 0.96 ]
Total events: 496 (Treatment), 612 (Control)
Heterogeneity: Tau2 = 0.01; Chi2 = 7.83, df = 7 (P = 0.35); I2 =11%
Test for overall effect: Z = 2.43 (P = 0.015)
2 Total cornary without PQRST
Castano 1999 0/31 1/31 0.2 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 3/29 0.2 % 0.14 [ 0.01, 2.80 ]
Coccheri 2002 1/143 6/143 0.4 % 0.16 [ 0.02, 1.35 ]
HPS 369/3384 465/3364 79.2 % 0.76 [ 0.66, 0.88 ]
LEADER 90/783 111/785 19.0 % 0.79 [ 0.59, 1.06 ]
Mohler 2003 7/240 3/114 0.9 % 1.11 [ 0.28, 4.38 ]
Nye 1973 0/23 1/23 0.2 % 0.32 [ 0.01, 8.25 ]
Subtotal (95% CI) 4631 4489 100.0 % 0.76 [ 0.67, 0.87 ]
Total events: 467 (Treatment), 590 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.19, df = 6 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 4.12 (P = 0.000039)
3 Total coronary excluding studies with moderate or high risk of bias
Castano 1999 0/31 1/31 0.2 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 3/29 0.2 % 0.14 [ 0.01, 2.80 ]
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(. . . Continued)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
HPS 369/3384 465/3364 80.3 % 0.76 [ 0.66, 0.88 ]
LEADER 90/783 111/785 19.3 % 0.79 [ 0.59, 1.06 ]
Subtotal (95% CI) 4225 4209 100.0 % 0.76 [ 0.67, 0.87 ]
Total events: 459 (Treatment), 580 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.56, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 4.03 (P = 0.000056)
4 Total coronary (HMG Co A Group / Statins)
HPS 369/3384 465/3364 98.9 % 0.76 [ 0.66, 0.88 ]
Mohler 2003 7/240 3/114 1.1 % 1.11 [ 0.28, 4.38 ]
Subtotal (95% CI) 3624 3478 100.0 % 0.77 [ 0.66, 0.89 ]
Total events: 376 (Treatment), 468 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 3.60 (P = 0.00032)
5 Total coronary (Policosanol group)
Castano 1999 0/31 1/31 46.4 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 3/29 53.6 % 0.14 [ 0.01, 2.80 ]
Subtotal (95% CI) 58 60 100.0 % 0.20 [ 0.02, 1.85 ]
Total events: 0 (Treatment), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 1.6. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 6 Fatal coronary
event.
Review: Lipid-lowering for peripheral arterial disease of the lower limb
Comparison: 1 Any lipid-lowering regimen vs control: all trials
Outcome: 6 Fatal coronary event
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fatal coronary: All studies
Coccheri 2002 1/143 3/143 2.3 % 0.33 [ 0.03, 3.20 ]
LEADER 64/783 65/785 93.3 % 0.99 [ 0.69, 1.41 ]
Mohler 2003 2/240 1/114 2.1 % 0.95 [ 0.09, 10.58 ]
Nye 1973 0/23 1/23 1.1 % 0.32 [ 0.01, 8.25 ]
PQRST 0/152 1/151 1.2 % 0.33 [ 0.01, 8.14 ]
Subtotal (95% CI) 1341 1216 100.0 % 0.94 [ 0.66, 1.33 ]
Total events: 67 (Treatment), 71 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.72, df = 4 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
2 Fatal coronary without PQRST
Coccheri 2002 1/143 3/143 2.4 % 0.33 [ 0.03, 3.20 ]
LEADER 64/783 65/785 94.4 % 0.99 [ 0.69, 1.41 ]
Mohler 2003 2/240 1/114 2.1 % 0.95 [ 0.09, 10.58 ]
Nye 1973 0/23 1/23 1.2 % 0.32 [ 0.01, 8.25 ]
Subtotal (95% CI) 1189 1065 100.0 % 0.95 [ 0.67, 1.34 ]
Total events: 67 (Treatment), 70 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.31, df = 3 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
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Analysis 1.7. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 7 Non-fatal coronary
event.
Review: Lipid-lowering for peripheral arterial disease of the lower limb
Comparison: 1 Any lipid-lowering regimen vs control: all trials
Outcome: 7 Non-fatal coronary event
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Non-fatal coronary: All studies
Castano 1999 0/31 1/31 1.5 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 3/29 1.7 % 0.14 [ 0.01, 2.80 ]
Coccheri 2002 0/143 3/143 1.8 % 0.14 [ 0.01, 2.73 ]
LEADER 26/783 46/785 52.8 % 0.55 [ 0.34, 0.90 ]
Mohler 2003 5/240 2/114 5.7 % 1.19 [ 0.23, 6.24 ]
PQRST 29/152 21/151 36.5 % 1.46 [ 0.79, 2.70 ]
Subtotal (95% CI) 1376 1253 100.0 % 0.73 [ 0.37, 1.45 ]
Total events: 60 (Treatment), 76 (Control)
Heterogeneity: Tau2 = 0.25; Chi2 = 9.04, df = 5 (P = 0.11); I2 =45%
Test for overall effect: Z = 0.89 (P = 0.38)
2 Non-fatal coronary without PQRST
Castano 1999 0/31 1/31 2.4 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 3/29 2.7 % 0.14 [ 0.01, 2.80 ]
Coccheri 2002 0/143 3/143 2.8 % 0.14 [ 0.01, 2.73 ]
LEADER 26/783 46/785 83.2 % 0.55 [ 0.34, 0.90 ]
Mohler 2003 5/240 2/114 8.9 % 1.19 [ 0.23, 6.24 ]
Subtotal (95% CI) 1224 1102 100.0 % 0.54 [ 0.34, 0.86 ]
Total events: 31 (Treatment), 55 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.59, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0085)
3 Non-fatal coroanry excluding studies with moderate or high risk of bias
Castano 1999 0/31 1/31 2.7 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 3/29 3.1 % 0.14 [ 0.01, 2.80 ]
LEADER 26/783 46/785 94.2 % 0.55 [ 0.34, 0.90 ]
Subtotal (95% CI) 841 845 100.0 % 0.53 [ 0.33, 0.85 ]
Total events: 26 (Treatment), 50 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 2 (P = 0.64); I2 =0.0%
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(. . . Continued)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Test for overall effect: Z = 2.62 (P = 0.0088)
4 Non-fatal coronary (Policosanol group)
Castano 1999 0/31 1/31 46.4 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 3/29 53.6 % 0.14 [ 0.01, 2.80 ]
Subtotal (95% CI) 58 60 100.0 % 0.20 [ 0.02, 1.85 ]
Total events: 0 (Treatment), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 1.8. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 8 Total stroke.
Review: Lipid-lowering for peripheral arterial disease of the lower limb
Comparison: 1 Any lipid-lowering regimen vs control: all trials
Outcome: 8 Total stroke
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Total stroke: All studies
Castano 1999 0/31 2/31 0.8 % 0.19 [ 0.01, 4.07 ]
Castano 2001 0/27 2/29 0.8 % 0.20 [ 0.01, 4.36 ]
Coccheri 2002 1/143 1/143 1.0 % 1.00 [ 0.06, 16.14 ]
HPS 179/3384 242/3364 64.2 % 0.72 [ 0.59, 0.88 ]
LEADER 60/783 49/785 32.5 % 1.25 [ 0.84, 1.84 ]
Mohler 2003 2/240 0/114 0.8 % 2.40 [ 0.11, 50.41 ]
Subtotal (95% CI) 4608 4466 100.0 % 0.88 [ 0.58, 1.33 ]
Total events: 242 (Treatment), 296 (Control)
Heterogeneity: Tau2 = 0.07; Chi2 = 8.15, df = 5 (P = 0.15); I2 =39%
Test for overall effect: Z = 0.61 (P = 0.54)
2 Total stroke excluding studies with moderate or high risk of bias
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(. . . Continued)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Castano 1999 0/31 1/31 0.7 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 3/29 0.8 % 0.14 [ 0.01, 2.80 ]
HPS 179/3384 242/3364 65.4 % 0.72 [ 0.59, 0.88 ]
LEADER 60/783 49/785 33.1 % 1.25 [ 0.84, 1.84 ]
Subtotal (95% CI) 4225 4209 100.0 % 0.86 [ 0.52, 1.41 ]
Total events: 239 (Treatment), 295 (Control)
Heterogeneity: Tau2 = 0.11; Chi2 = 7.61, df = 3 (P = 0.05); I2 =61%
Test for overall effect: Z = 0.62 (P = 0.54)
3 Total stroke (HMG Co A Group / Statins)
HPS 179/3384 242/3364 98.1 % 0.72 [ 0.59, 0.88 ]
Mohler 2003 2/240 1/114 1.9 % 0.95 [ 0.09, 10.58 ]
Subtotal (95% CI) 3624 3478 100.0 % 0.72 [ 0.59, 0.88 ]
Total events: 181 (Treatment), 243 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 3.21 (P = 0.0013)
4 Total stroke (Policosanol group)
Castano 1999 0/31 2/31 50.1 % 0.19 [ 0.01, 4.07 ]
Castano 2001 0/27 2/29 49.9 % 0.20 [ 0.01, 4.36 ]
Subtotal (95% CI) 58 60 100.0 % 0.19 [ 0.02, 1.71 ]
Total events: 0 (Treatment), 4 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
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Analysis 1.9. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 9 Fatal stroke.
Review: Lipid-lowering for peripheral arterial disease of the lower limb
Comparison: 1 Any lipid-lowering regimen vs control: all trials
Outcome: 9 Fatal stroke
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Fatal stroke: All studies
Castano 1999 0/31 1/31 5.4 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 1/29 5.4 % 0.35 [ 0.01, 8.85 ]
Coccheri 2002 0/143 1/143 5.5 % 0.33 [ 0.01, 8.19 ]
LEADER 13/783 9/785 78.0 % 1.46 [ 0.62, 3.43 ]
Mohler 2003 1/240 0/114 5.6 % 1.43 [ 0.06, 35.48 ]
Subtotal (95% CI) 1224 1102 100.0 % 1.14 [ 0.54, 2.43 ]
Total events: 14 (Treatment), 12 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.02, df = 4 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.73)
2 Fatal stroke excluding studies with moderate or high risk of bias
Castano 1999 0/31 1/31 6.1 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 1/29 6.1 % 0.35 [ 0.01, 8.85 ]
LEADER 13/783 9/785 87.8 % 1.46 [ 0.62, 3.43 ]
Subtotal (95% CI) 841 845 100.0 % 1.22 [ 0.55, 2.71 ]
Total events: 13 (Treatment), 11 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.40, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
3 Fatal stroke (Policosanol group)
Castano 1999 0/31 1/31 50.1 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 1/29 49.9 % 0.35 [ 0.01, 8.85 ]
Subtotal (95% CI) 58 60 100.0 % 0.33 [ 0.03, 3.30 ]
Total events: 0 (Treatment), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
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Analysis 1.10. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 10 Non-fatal stroke.
Review: Lipid-lowering for peripheral arterial disease of the lower limb
Comparison: 1 Any lipid-lowering regimen vs control: all trials
Outcome: 10 Non-fatal stroke
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Non-fatal stroke: All studies
Castano 1999 0/31 1/31 1.7 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 1/29 1.7 % 0.35 [ 0.01, 8.85 ]
Coccheri 2002 1/143 0/143 1.7 % 3.02 [ 0.12, 74.78 ]
LEADER 47/783 40/785 93.3 % 1.19 [ 0.77, 1.84 ]
Mohler 2003 1/240 0/114 1.7 % 1.43 [ 0.06, 35.48 ]
Subtotal (95% CI) 1224 1102 100.0 % 1.16 [ 0.76, 1.77 ]
Total events: 49 (Treatment), 42 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.51, df = 4 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
2 Non-fatal stroke without studies with moderate or high risk of bias
Castano 1999 0/31 1/31 1.7 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 1/29 1.7 % 0.35 [ 0.01, 8.85 ]
LEADER 47/783 40/785 96.5 % 1.19 [ 0.77, 1.84 ]
Subtotal (95% CI) 841 845 100.0 % 1.14 [ 0.74, 1.74 ]
Total events: 47 (Treatment), 42 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.14, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
3 Non-fatal stroke (Policosanol group)
Castano 1999 0/31 1/31 50.1 % 0.32 [ 0.01, 8.23 ]
Castano 2001 0/27 1/29 49.9 % 0.35 [ 0.01, 8.85 ]
Subtotal (95% CI) 58 60 100.0 % 0.33 [ 0.03, 3.30 ]
Total events: 0 (Treatment), 2 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
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Analysis 1.11. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 11 Revascularization
(HMG Co A Group / Statins).
Review: Lipid-lowering for peripheral arterial disease of the lower limb
Comparison: 1 Any lipid-lowering regimen vs control: all trials
Outcome: 11 Revascularization (HMG Co A Group / Statins)
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
HPS 466/3384 603/3364 99.7 % 0.73 [ 0.64, 0.83 ]
Mohler 2003 1/240 2/114 0.3 % 0.23 [ 0.02, 2.61 ]
Total (95% CI) 3624 3478 100.0 % 0.73 [ 0.64, 0.83 ]
Total events: 467 (Treatment), 605 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 4.72 (P < 0.00001)
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Analysis 1.12. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 12 Pain-free walking
distance (PFWD).
Review: Lipid-lowering for peripheral arterial disease of the lower limb
Comparison: 1 Any lipid-lowering regimen vs control: all trials
Outcome: 12 Pain-free walking distance (PFWD)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 PFWD: All studies
Castano 1999 31 205.7 (202.11) 31 129.6 (98.55) 13.4 % 76.10 [ -3.05, 155.25 ]
Castano 2001 27 333.5 (148.6) 29 117.4 (21.8) 15.9 % 216.10 [ 159.49, 272.71 ]
Corsi 1985 15 355 (259) 15 180 (174) 6.9 % 175.00 [ 17.10, 332.90 ]
Cospite 1985 15 275 (98.6) 15 255 (55.8) 15.8 % 20.00 [ -37.33, 77.33 ]
Gans 1990 16 99 (61.6) 16 127 (65.2) 17.2 % -28.00 [ -71.95, 15.95 ]
Mondillo 2003 43 190 (38) 43 100 (34) 19.3 % 90.00 [ 74.76, 105.24 ]
Palmieri 1984 11 295.4 (143.7) 10 160 (73.5) 11.6 % 135.40 [ 39.03, 231.77 ]
Subtotal (95% CI) 158 159 100.0 % 89.76 [ 30.05, 149.47 ]
Heterogeneity: Tau2 = 5094.47; Chi2 = 53.65, df = 6 (P<0.00001); I2 =89%
Test for overall effect: Z = 2.95 (P = 0.0032)
2 PFWD (Policosanol group)
Castano 1999 31 205.7 (20.11) 31 129.6 (98.55) 55.6 % 76.10 [ 40.69, 111.51 ]
Castano 2001 27 333.5 (148.6) 29 137.9 (117.4) 44.4 % 195.60 [ 125.12, 266.08 ]
Subtotal (95% CI) 58 60 100.0 % 131.80 [ 14.97, 248.64 ]
Heterogeneity: Tau2 = 6330.40; Chi2 = 8.82, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 2.21 (P = 0.027)
3 PFWD (Sulodexide)
Corsi 1985 15 355 (259) 15 180 (174) 20.1 % 175.00 [ 17.10, 332.90 ]
Cospite 1985 15 275 (98.6) 15 255 (55.8) 46.1 % 20.00 [ -37.33, 77.33 ]
Palmieri 1984 11 295.4 (143.7) 10 160 (73.5) 33.9 % 135.40 [ 39.03, 231.77 ]
Subtotal (95% CI) 41 40 100.0 % 94.15 [ -5.33, 193.62 ]
Heterogeneity: Tau2 = 5081.61; Chi2 = 6.26, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 1.85 (P = 0.064)
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Analysis 1.13. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 13 Total walking
distance (TWD).
Review: Lipid-lowering for peripheral arterial disease of the lower limb
Comparison: 1 Any lipid-lowering regimen vs control: all trials
Outcome: 13 Total walking distance (TWD)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 TWD: All studies
Castano 1999 31 365.4 (261.13) 31 224.9 (149.21) 23.2 % 140.50 [ 34.63, 246.37 ]
Castano 2001 27 648.9 (281.11) 29 237.7 (146.01) 22.3 % 411.20 [ 292.60, 529.80 ]
Gans 1990 16 129 (49.6) 16 152 (80) 26.8 % -23.00 [ -69.12, 23.12 ]
Mondillo 2003 43 230 (45) 43 104 (29) 27.7 % 126.00 [ 110.00, 142.00 ]
Subtotal (95% CI) 117 119 100.0 % 152.00 [ 32.11, 271.88 ]
Heterogeneity: Tau2 = 13318.95; Chi2 = 60.39, df = 3 (P<0.00001); I2 =95%
Test for overall effect: Z = 2.48 (P = 0.013)
2 TWD (Policosanol group)
Castano 1999 31 365.4 (261.13) 31 224.9 (149.21) 51.0 % 140.50 [ 34.63, 246.37 ]
Castano 2001 27 648.9 (281.11) 29 237.7 (146.01) 49.0 % 411.20 [ 292.60, 529.80 ]
Subtotal (95% CI) 58 60 100.0 % 274.48 [ 9.21, 539.74 ]
Heterogeneity: Tau2 = 33349.38; Chi2 = 11.14, df = 1 (P = 0.00085); I2 =91%
Test for overall effect: Z = 2.03 (P = 0.043)
-1000 -500 0 500 1000
Favours control Favours treatment
55Lipid-lowering for peripheral arterial disease of the lower limb (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.14. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 14 Ankle brachial
index (ABI).
Review: Lipid-lowering for peripheral arterial disease of the lower limb
Comparison: 1 Any lipid-lowering regimen vs control: all trials
Outcome: 14 Ankle brachial index (ABI)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 ABI: All studies
Castano 1999 31 0.63 (0.39) 31 0.57 (0.28) 5.8 % 0.06 [ -0.11, 0.23 ]
Castano 2001 27 0.71 (0.31) 29 0.64 (0.32) 6.0 % 0.07 [ -0.10, 0.24 ]
Corsi 1985 15 0.56 (0.12) 15 0.47 (0.12) 15.5 % 0.09 [ 0.00, 0.18 ]
Gans 1990 16 0.53 (0.14) 16 0.58 (0.14) 13.3 % -0.05 [ -0.15, 0.05 ]
Mohler 2003 240 0.64 (0.22) 114 0.63 (0.11) 30.3 % 0.01 [ -0.02, 0.04 ]
Mondillo 2003 43 0.65 (0.08) 43 0.56 (0.1) 29.0 % 0.09 [ 0.05, 0.13 ]
Subtotal (95% CI) 372 248 100.0 % 0.04 [ -0.01, 0.09 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 14.14, df = 5 (P = 0.01); I2 =65%
Test for overall effect: Z = 1.72 (P = 0.085)
2 ABI (Policosanol group)
Castano 1999 31 0.63 (0.39) 31 0.57 (0.28) 49.0 % 0.06 [ -0.11, 0.23 ]
Castano 2001 27 0.71 (0.31) 29 0.64 (0.32) 51.0 % 0.07 [ -0.10, 0.24 ]
Subtotal (95% CI) 58 60 100.0 % 0.07 [ -0.05, 0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
3 ABI (HMG Co A Group / Statins)
Mohler 2003 240 0.64 (0.22) 114 0.63 (0.11) 51.1 % 0.01 [ -0.02, 0.04 ]
Mondillo 2003 43 0.65 (0.08) 43 0.56 (0.1) 48.9 % 0.09 [ 0.05, 0.13 ]
Subtotal (95% CI) 283 157 100.0 % 0.05 [ -0.03, 0.13 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 9.29, df = 1 (P = 0.002); I2 =89%
Test for overall effect: Z = 1.24 (P = 0.22)
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A D D I T I O N A L T A B L E S
Table 1. Methodological quality assessment
Study ID Allocation Base-
line com-
parable
Intention
to treat
Blindness Overall
score
Loss to
follow up
Inclusion
criteria
Exclusion
criteria
Outcome
Bonalumi
1986
B A C A (DB) C Not
reported
B C A
Caramelli
1988
B A B (not
clear)
A (DB) B None A C A
Castano
1999
A A A A (DB) A 16% A A A
Castano
2001
A A A A (DB) A 28% A A A
Castano
2003
A A A A (DB) A 3% A A A
Cocheri
2002
B A A A (DB) B 18% A A A
Corsi 1985 A A B (not
clear)
A (DB) B None A A A
Cospite
1985
A A B (not
clear)
A (DB) B None A A A
Gans 1990 A A C A (DB) C 14% A A A
HPS A A A A (DB) A Compli-
ance with
statin use
in treat-
ment arm
is 85%. %
us-
ing statin
in placebo
arm is 17%
A A A
Leader
trial
A A A A (DB) A 45% A A A
Liguori
1993
B A B (not
clear)
A (DB) B 9% A A B
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Table 1. Methodological quality assessment (Continued)
Mohler
2003
B A C A (DB) C 3% A A A
Mondillo
2003
B A A A (DB) B None A A A
Nye 1973 B A B (not
clear)
A (DB) B 32% A B A
Palmieri
1984
B B C A (DB) C None A C A
PQRST B A B A (DB) B 10% A A A
St.Thomas B B B B
(outcome
assessor
blinded)
B 4% A A A
Table 2. Events contributing to vascular outcomes
Study ID Total cardio-
vascular
Non-fatal
cardiovasc
Fatal cardio-
vasc
Total
coronary
Non-fatal
coronary
Total stroke Source of
data
Castano 1999 Angina,
TIA, non- fa-
tal stroke; fatal
stroke
Angina;
TIA; non-fatal
stroke
Fatal stroke Angina Angina Fatal and non-
fatal stroke
From adverse
events
Castano 2001 Fatal and non-
fatal
cardiovascular
TIA; MI; un-
stable angina;
non-fatal
stroke
Fatal stroke MI; unstable
angina
MI; unstable
angina
Fatal and non-
fatal stroke
From
withdrawals
Coccheri
2002
Angina; acute
leg ischaemia;
non-fatal MI;
fatal stroke; fa-
tal MI
Angina; acute
leg ischaemia;
non-fatal MI
Fatal MI and
stroke
Fatal and non-
fatal AMI;
angina
Non-fatal
AMI; angina
Fatal and non-
fatal stroke
From serious
adverse events
HPS Non-fatal MI
or fatal CHD;
strokes of any
type and coro-
nary or non-
coro-
nary revascu-
larisations
Predefined
outcome
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Table 2. Events contributing to vascular outcomes (Continued)
Leader trial Fatal and non-
fatal
cardiovascular
Non-fatal
coronary heart
disease; non-
fatal stroke
Fatal coronary
heart
disease and fa-
tal stroke
Sudden coro-
nary death;
non-fatal MI
Non-fatal MI Fatal and non-
fatal stroke
Predefined
outcome
Mohler 2003 Fatal and non-
fatal MI and
stroke
MI; stroke Fatal MI and
stroke
Fatal MI and
coronary heart
disease; non-
fatal MI
Non fatal MI Fatal and non-
fatal stroke
From discon-
tinuation
from studies
Nye Severe coro-
nary heart dis-
ease problem,
Severe coro-
nary heart dis-
ease problem;
carotid occlu-
sion
Death from
carotid occlu-
sion, coronary
thrombosis
Fromdrop out
information
PQRST MI
(acute, silent,
possible silent)
; angina; ar-
rhythmias;
other
heart disease,
TIA; fatal MI
MI
(acute, silent,
possible silent)
; angina; ar-
rhythmias;
other heart
disease; TIA
Fatal MI Fatal and non-
fatal AMI in-
cluding silent
infarct; angina
Non fa-
tal AMI; silent
AMI; angina
From
withdrawals
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Arterial Occlusive Diseases, this term only
#2 arter* near occlus*
#3 periph* near arter*
#4 obstruct* near arter*
#5 PAOD
#6 PAD
#7 (#1 OR #2 OR #3 OR #4 OR #5 OR #6)
#8 MeSH descriptor Intermittent Claudication, this term only
#9 intermitt* near claud*
#10 claud*
#11 (#8 OR #9 OR #10)
#12 limb ischem*
#13 critical near limb
#14 (#12 OR #13)
#15 (#11 OR #14)
#16 lipid near lower*
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#17 statin* or simvastatin* or atorvastatin* or fibrate* or HMG-COA
#18 hydroxymethylglutaryl-coa-reduct* or probucol* or niacin* or nicotin* near acid*
#19 MeSH descriptor Hydroxymethylglutaryl CoA Reductases explode all trees
#20 MeSH descriptor Probucol, this term only
#21 MeSH descriptor Niacin, this term only
#22 (#16 OR #17 OR #18 OR #19 OR #20 OR #21)
#23 (#15 AND #22)
WH A T ’ S N E W
Last assessed as up-to-date: 11 July 2007.
Date Event Description
24 October 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 2, 1996
Review first published: Issue 3, 1996
Date Event Description
12 July 2007 New citation required and conclusions have changed Review substantively updated.
1) The title of this review has been amended from ’Lipid-
lowering for lower limb atherosclerosis’ to reflect more accu-
rately the content of the review.
2) Thirteen new included studies and 51 new excluded stud-
ies have been added.
3) There is a new contact author and an additional co-author
C O N T R I B U T I O N S O F A U T H O R S
Updated version of the review (August 2007):
Phyu Phyu Aung: selected trials for inclusion in the review, assessed trial quality, extracted data, and wrote the text.
Heather Maxwell: searched the PVD Group’s Trials Register and The Cochrane Library for potential trials, selected trials for inclusion
in the review, assessed trial quality, extracted data, and contributed to the text.
Ruth Jepson: selected trials for inclusion in the review, assessed trial quality, and extracted data.
Jackie Price: cross-checked trials for inclusion and quality, confirmed data extraction, and contributed to the text.
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Gillian Leng: commented on the text.
Original version of the review:
GillianLeng: identifiedpossible trials, and assessed their eligiblity and quality; sought additional information fromprincipal investigators
of all trials that appeared to meet the inclusion criteria. Extracted data, wrote text.
Jackie Price: cross-checked trials for inclusion in the review, and quality; extracted data.
Ruth Jepson: assisted in the identification of trials for the review, and provided general advice and guidance on methodological issues.
D E C L A R A T I O N S O F I N T E R E S T
JP has received research funding from Pfizer plc and Bayer plc.
S O U R C E S O F S U P P O R T
Internal sources
• University of Edinburgh, UK.
External sources
• Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government, UK.
• British Heart Foundation, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The title of this review has been amended from ’Lipid-lowering for lower limb atherosclerosis’ to reflect more accurately the content of
the review.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Arteriosclerosis [∗drug therapy]; Hypolipidemic Agents [∗therapeutic use]; Leg [∗blood supply]; Peripheral Vascular Diseases [∗drug
therapy]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans; Male
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